


















The Dissertation Committee for Huda Sirageldin Suliman Certifies that this 
is the approved version of the following dissertation: 
 
Characterization of Cobalamin-Independent Methionine Synthase 





Jon D. Robertus, Supervisor 
Dean R. Appling 
Karen Browning 
Paul J. Szaniszlo 






Characterization of Cobalamin-Independent Methionine Synthase 








Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 



















 I would like to thank my advisor, Dr. Jon Robertus for his support and 
guidance.  I benefited greatly from his knowledge and wisdom.  I would also like 
to thank Dr. Dean Appling, a valued collaborator, who introduced me to yeast and 
always was available for discussions.  Also many thanks the other members of my 
committee, Dr. Karen Browning, Dr. Paul Szaniszlo, and Dr. John Tesmer, for 
their helpful suggestions in this work.   
 Many thanks to my fellow lab members past and present, who have 
provided a wonderful social and academic environment:  Jennifer Sadow, John 
Pascal, Man Zhang, Wendi Wagner, Warren Hoe, Jennifer Schleit, Matthew 
Lluis, Yan Bai, Shuangluo Xia, Arthur Monzingo, Steve Ernst, and Gregory 
Sawyer.  I would also like to thank Margaret Rodgers and Natalie Potts for their 
patience and effort in managing financial and administrative matters. 
 v
Characterization of Cobalamin-Independent Methionine Synthase 





Huda Sirageldin Suliman, Ph.D. 
The University of Texas at Austin, 2006 
 
Supervisor:  Jon D. Robertus 
 
Methionine synthases are folate-dependent enzymes that catalyze the 
transfer of a methyl group from 5-methyltetrahydropteroylpolyglutamate (CH3–
H4PteGlun), also called 5-methyltetrahydrofolate, to L-homocysteine to form L-
methionine.  There are two major classes of methionine synthases, the cobalamin-
dependent and the cobalamin-independent methionine synthases.   
The cobalamin-dependent methionine synthase is a very large, 140 kDa 
protein, and uses cobalamin to aid in the transfer of the methyl group from 5-
CH3–H4PteGlun to homocysteine.  Only organisms that can synthesize or obtain 
cobalamin, such as mammals, use cobalamin-dependent methionine synthase. 
Organisms that cannot obtain or synthesize cobalamin, such as fungi, use 
the cobalamin-independent methionine synthases, and some bacteria such as E. 
coli use enzymes from both classes.  Proteins from the cobalamin-independent 
 vi
class have a molecular weight of 86 kDa, and have no amino acid sequence 
homology to the cobalamin-dependent enzymes.  These enzymes are zinc 
dependent, and kinetic analyses of the E. coli cobalamin-independent methionine 
synthase (MetEp) reveal that it will only bind polyglutamated forms of 5-CH3–
H4PteGlun.  Methionine synthases from fungi are not well characterized.  They 
may be interesting anti-fungal drug targets because of the mechanistic differences 
between them and the cobalamin-dependent forms present in humans. 
C. albicans resides in the normal flora of the human body.  However, it is 
able to cause infection in immunocompromised patients.  In the past two decades, 
C. albicans has become one of the most common opportunistic pathogens, 
particularly in hospitals.  Increasing drug resistance to present drugs, and severe 
side effects results in the constant search for new drug targets to create better and 
more effective therapies. 
The work presented here investigates the cobalamin-independent 
methionine synthase from C. albicans (CaMet6p) and from S. cerevisiae 
(ScMet6p).  Substrate specificity for both enzymes was explored through kinetic 
analyses, and a strategy was implemented to study important active site residues 
by site-directed mutagenesis.  A conditional cobalamin-independent methionine 
synthase (CaMET6) mutant in C. albicans was constructed, using the PCR-based 
gene disruption method, to assess the viability of the resulting null mutant strain.  
 vii
The results from these experiments have provided new insights into enzyme 
function, and support the study of CaMet6p as an anti-fungal drug target. 
 
 viii
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CHAPTER 1:  INTRODUCTION 
Methionine synthases catalyze the transfer of a methyl group from 5-
methyltetrahydropteroylpolyglutamate (5-CH3-H4PteGlun) to L-homocysteine 
(Hcy) to form L-methionine, in the last step of methionine biosynthesis (Figure 
1.1).  These enzymes mark the convergence between the methionine metabolism 
pathway and the one-carbon metabolism pathway (Figure 1.1).  Folate mediated 
one-carbon metabolism plays an essential role in the synthesis of nucleotides, 
vitamins, and some amino acids (Cossins et al., 1997; Piper et al., 2000).  Only 
the tetrahydro- form of folate is active, and dihydrofolate reductase catalyzes the 
reduction of folic acid to dihydrofolate (DHF), and then to tetrahydrofolate 
(H4PteGlun)(Figure 1.2).  H4PteGlun has three main structural features: a pteridine 
ring, p-aminobenzoic acid (PABA), and a polyglutamate chain (Figure 1.3).  
Serine, glycine, and formate provide the one-carbon units, which are activated by 
attachment to tetrahydrofolate (H4PteGlun) (Piper et al., 2000).  One-carbon 
metabolism in yeast is compartmentalized, where one-carbon units are 
interconverted between the mitochondria and cytoplasm (Figure 1.4).  Serine 
hydroxymethyl transferase catalyzes the conversion of H4PteGlun into 5, 10 
methylenetetrahydrofolate (5, 10-CH2-H4PteGlun) through the conversion of 
serine to glycine (Figure 1.4).  Several pathways also involve 5, 10 methylene-
H4PteGlun.  For example, 5, 10 methylenetetrahydrofolate can be used to convert 
dUMP to dTMP using thymidylate synthase (Figure 1.5).  It can also be oxidized 
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to form 10-formyl-H4PteGlun, which is used in the synthesis of purines (Figure 
1.5).  5, 10-CH2-H4PteGlun can also be reduced to 5-CH3-H4PteGlun catalyzed by 
5, 10 methylene tetrahydrofolate reductase (MTHFR).  The 5-CH3- H4PteGlun 
created is then used by methionine synthase to synthesize methionine from 




















Figure 1.1  Biosynthesis of sulfur amino acids.  Enzymes: 1, ATP sulfurylase; 2, 
APS kinase; 3, PAPS reductase; 4, sulfite reductase; 5, homocysteine synthase; 6, 
homoserine O-acetyltransferase; 7, methionine synthase; 8, cystathionine β-
synthase; 9, cystathionine γ-lyase.  Methionine synthase accepts 5-
methyltetrahydrofolate (5-CH3-H4PteGlun) from the one carbon pathway as a 
substrate, and produces tetrahydrofolate (H4PteGlun).  Enzymes in folate 





















Figure 1.3 The structure of tetrahydrofolate (H4PteGlun).  The N-5 and N-10 




Figure 1.4 Compartmentalization of one-carbon metabolism.  The metabolic 
system in the mitochondria and cytoplasm are similar, and one-carbon units are 







Figure 1.5 Products of one-carbon metabolism. 
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Methionine is one of two sulfur-containing amino acids, and it is the first 
amino acid in most protein, since its DNA codon is usually the point of translation 
initiation.  More importantly, methionine is activated with ATP to form S-
adenosylmethionine (AdoMet), by the enzyme methionine adenosyltransferase 
(Figure 1.6).  S-adenosylmethionine is an important methyl donor, and is the 
second most commonly used metabolic cofactor, the first being ATP (Kozbial et 
al., 2005).  Each cellular organism has several AdoMet-utilizing enzymes 
(Kozbial et al., 2005), with which AdoMet donates methyl groups for covalent 
modification of a variety of substrates.  Methylation of DNA is important for the 
regulation of gene expression, and methylation regulates hormones, 
neurotransmitters, and signal-transduction systems (Fontecave et al., 2004).  S-
adenosylhomocysteine (AdoHcy) is a product of these methyl transfers (Figure 
1.6).  AdoHcy is then hydrolyzed by S-adenosylhomocysteine hydrolase to form 
homocysteine, which can re-enter the methionine metabolism pathway through 
the action of methionine synthase (Figure 1.6).   
There are two major classes of methionine synthases, cobalamin-
dependent, and cobalamin-independent methionine synthases (Gonzalez et al., 
1992; Matthews et al., 2003).  Organisms that can acquire, or synthesize 
cobalamin use cobalamin-dependent methionine synthases, and organisms that 
cannot acquire or synthesize cobalamin use cobalamin-independent methionine 
synthases.  Mammals use only cobalamin-dependent methionine synthase, and 
 6
yeasts and plants use only the cobalamin-independent methionine synthase.  Some 




Figure 1.6  The S-adenosylmethionine (AdoMet) cycle.  X represents a methyl 
acceptor.  Methionine reacts with ATP to form AdoMet catalyzed by (1) S-
adenosylmethionine synthetase;  (2)  methyltransferases transfer the methyl group 
from AdoMet to a methyl acceptor forming S-adenosylhomocysteine (AdoHcy); 
(3) AdoHcy is hydrolyzed by S-adenosylhomocysteine hydrolase to form 
homocysteine (Hcy); (4)  methionine is regenerated when methionine synthase 
methylates homocysteine.  
 
 
COBALAMIN-DEPENDENT METHIONINE SYNTHASE 
 The most extensively studied cobalamin-dependent methionine synthase is 
the MetH enzyme from Escherichia coli (Matthews, 2001).  Cobalamin-
dependent methionine synthase catalyzes the conversion of homocysteine and 5-
CH3-H4PteGlun to methionine and H4PteGlun in two steps (Figure 1.7).  In the 
first step, the methyl group is transferred from 5-CH3-H4PteGlun to cob(I)alamin, 
producing methylcobalamin and H4PteGlun.  The methyl group is then transferred 
from methylcobalamin to homocysteine forming methionine and cob(I)alamin.  
Occasionally cob(I)alamin is oxidized to the inactive cob(II)alamin form, which is 
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then reactivated by reductive methylation where flavodoxin is the electron donor 
and AdoMet is the methyl donor (Figure 1.7) (Goulding et al., 1997).    The 
cobalamin-dependent methionine synthases are very large proteins, roughly 140 
kDa.  They appear to have four major domains, which function in binding L-
homocysteine, CH3–H4PteGlun, cobalamin, and AdoMet respectively (Goulding et 
al., 1997). 
The X-ray structure of the two amino terminal domains of the enzyme 
from Thermotoga maratima has been reported (Evans et al., 2004), as have 
structures for the cobalamin-binding domain (Drennan et al., 1994) and the 
AdoMet binding domain of the E. coli enzyme (Dixon et al., 1996).  The 
structures show that each domain is activated by its own substrate-binding site.  
Three of the domains are involved in methyl transfer and the fourth domain is 
involved in AdoMet binding (Evans et al., 2004).   Kinetic analysis shows that the 







Figure 1.7  The enzymatic reactions catalyzed by MetHp.  A methyl group is 
transferred from CH3-H4folate to the cob(I)alamin cofactor bound to MetHp, 
forming H4-folate and methylcobalamin. The methyl group is then transferred 
from methylcobalamin to homocysteine, forming methionine and regenerating 








HUMAN METHIONINE SYNTHASE 
 In human metabolism methionine is an essential amino acid, and sufficient 
amounts are generally obtained through diet.  Methionine synthase is one of only 
two known cobalamin-dependent enzymes, the other being methylmalonyl-CoA 
mutase (Kolhouse et al., 1977).  Human methionine synthase is widely distributed 
in tissues, and serves as part of the methionine salvage pathway (Figure 1.8) 
(Stipanuk et al., 2004).  Homocysteine is a byproduct of methionine metabolism, 
but increased homocysteine levels in the blood, due to defects in this pathway, 
cause human disease.  Accumulated homocysteine is associated with 
cardiovascular disease, and promotes arteriosclerosis (Jakubowski et al., 2004).  
Homocysteine build up is implicated as a cause for neural tube defects, 









Figure 1.8  Methionine Salvage Pathway Enzymes: 1, methionine 
adenosyltransferase; 2, methyltransferase requiring AdoMet as the methyl donor; 
3, S-adenosylhomocysteine methyltransferase; 4, cobalamin-dependent 

















BETAINE HOMOCYSTEINE METHYLTRANSFERASE 
A second methyltransferase involved in human methionine metabolism, 
called betaine homocysteine methyltransferase (BHMT), does not require 
cobalamin.  BHMT is a hexamer of 45 kDa subunits (Millian et al., 1998), and is 
present only in the liver, kidneys, and lens of humans (Stipanuk, 2004).  BHMT is 
a zinc metalloenzyme catalyzing the transfer of the methyl group from betaine to 
homocysteine, forming dimethylglycine and methionine (Figure 1.9).  A proposed 
transition-state structure is shown in Figure 1.10, along with a transition-state 
analog (Evans et al., 2002; Castro et al., 2004).  This transition-state analog was 
used in crystal structures to define contacts for both substrates (Evans et al., 

































































Figure 1.9  The reaction catalyzed by betaine homocysteine methyltransferase 
(BHMT).  A methyl is transferred from betaine to L-homocysteine, forming L-





















































Transition State Analog  
 
Figure 1.10  The proposed transition state structure, and a transition state analog 










COBALAMIN-INDEPENDENT METHIONINE SYNTHASE 
Cobalamin-independent methionine synthases are large enzymes, 
generally around 86 kDa.  They have no obvious amino acid sequence homology 
with the cobalamin-dependent enzymes (Gonzales et al., 1992).  Cobalamin-
independent methionine synthases catalyze the conversion of 5-CH3-H4PteGlun 
and L-homocysteine to L-methionine and H4PteGlun, as shown in equation 1.  5-
CH3-H4PteGlun acts as the methyl donor and L-homocysteine is the methyl 
acceptor.   
 
5-CH3-H4PteGlun + L-homocysteine  H4PteGlun + L-methionine (1) 
 
Cobalamin-independent methionine synthases are zinc dependent enzymes 
(Gonzales et al., 1996; Zhou et al., 1999); they use the active site zinc to bind and 
activate the L-homocysteine substrate (Matthews et al., 2003).  The most studied 
cobalamin-independent methionine synthase is MetEp from E. coli.  Inductively 
coupled plasma-atomic emission spectrometry (ICP) showed that MetEp has one 
equivalent of zinc for each protein subunit (Gonzalez et al., 1996). A conserved 
cysteine in the C-terminal half of MetEp, Cys726, is required for zinc binding, 
which was determined through site-directed mutagenesis.  The mutant enzyme, 
Cys726Ser, showed no bound zinc using ICP and was inactive (Gonzalez et al., 
1996).  Kinetic analyses of the cobalamin-independent enzyme from E. coli show 
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that it will accept only polyglutamated forms of 5-CH3-H4PteGlun.  The turnover 
number for MetEp is 23/min, which is about 50-fold lower than the turnover 
number determined for MetHp, the cobalamin-dependent enzyme (Gonzalez et 
al., 1996). 
CURRENT COBALAMIN-INDEPENDENT METHIONINE SYNTHASE STRUCTURES 
 Currently there are two three-dimensional crystal structures of cobalamin-
independent methionine synthases.  The first structure reported is the 765 amino 
acid enzyme from the higher plant Arabidopsis thaliana, AtMetEp (Ferrer et al., 
2004)(Sequence alignment Figure 1.11).  This structure can be found in the RCSB 
Protein Data Bank (http://www.rcsb.org/pdb/) with ID numbers of 1U1H, 1U1J, 
1U1U, and 1U22.  AtMetEp crystals reveal a monomeric protein in which each 
monomer is composed of two domains that create a deep groove at the interface 
(Figure 1.12) (Ferrer et al., 2004).  The N-terminal domain extends from residues 
2 to 391, called the folate barrel, and the C-terminal domain extends from 
residues 392 to 765, called the homocysteine barrel.  The two domains are 
connected by loop 390-395.  Both domains are structurally similar, and form an 
eightfold (βα) repeat.  This structure is also known as a TIM (triose phosphate 
isomerase) barrel; each domain consists of eight parallel β-sheets surrounded by 
eight α-helices (Wierenga et al., 2001).  The TIM barrel fold is the most common 
fold among all the known protein structures.  In AtMetEp, the two TIM barrels 
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face each other forming one active site between the domains, and forming a cleft 
that allows the substrates to enter (Ferrer et al., 2004). 
 The active site of AtMetEp is located in the C-terminal domain.  The 
active site zinc of AtMetEp binds to the sulfur atom of Cys 649, Cys 733, and to 
the side chain nitrogen of His 647 (Figure 1.13).  These residues are homologous 
to the zinc binding residues determined for E. coli by site-directed mutagenesis 
(Zhou et al., 1999; Peariso et al., 2001).  There is a water molecule, W1, in close 
proximity to the active site zinc, 2-3 Å.  Homocysteine was observed at a distance 
of 3.6-4.4Å from the active site zinc atom, and the sulfur of homocysteine does 
not interact strongly with the zinc atom (Figure 1.14) (Ferrer et al., 2004).  The 
pteridine ring of CH3-H4PteGlu5 protrudes toward the zinc atom, and makes 
stacking interactions with Trp567 (Figure 1.15).  The methyl group from CH3-
H4PteGlu5 is about 7Å from the sulfur of homocysteine.  The p-aminobenzoate 
moiety had weak electron density and could not be modeled (Ferrer et al., 2004).  
Only the first glutamyl residue of CH3-H4PteGlu5 appeared in the electron density 
map, and is bound in a positively charged binding pocket created with loop 507-
529 (Figure 1.15)(Ferrer et al., 2004).  The glutamyl residue has ionic interactions 











ScMet6          -MVQSAVLGFPRIGPNRELKKATEGYWNGKITVDELFKVGKDLRTQNWKLQKEAGVDIIP 59 
CaMet6          -MVQSSVLGFPRIGGQRELKKITEAYWSGKATVEELLAKGKELREHNWKLQQKAGVDIIP 59 
EcMetE          MTILNHTLGFPRVGLRRELKKAQESYWAGNSTREELLAVGRELRARHWDQQKQAGIDLLP 60 
AtMetE          --MASHIVGYPRMGPKRELKFALESFWDGKSTAEDLQKVSADLRSSIWKQMSAAGTKFIP 58 
TmMetE          --MKAYAFGFPKIGEKREFKKALEDFWKGKITEEQFEEEMNKLRMYMVENYRKN-VDVIP 57 
                  :    .*:*::* .**:*   * :* *: * :::     .**    .       ..:* 
 
ScMet6          SNDFSFYDQVLDLSLLFNVIPDRYTKYDLSP-IDTLFAMGRGLQRKATETEKAVDVTALE 118 
CaMet6          SNDFSYYDQVLDLSLLFNAIPERYTKFDLAP-IDVLFAMGRGLQKKATETQAAVDVTALE 118 
EcMetE          VGDFAWYDHVLTTSLLLGNVPARHQNKDGSVDIDTLFRIGRGRAPTGEP------AAAAE 114 
AtMetE          SNTFAHYDQVLDTTAMLGAVPPRYGYTGGEIGLDVYFSMARGNAS----------VPAME 108 
TmMetE          SNELSYYDFVLDTAVMVGAVPERFGEYRGLS---TYFDMARG-------------GKALE 101 
                 . :: ** **  : :.. :* *.          . * :.**               * * 
 
ScMet6          MVKWFDSNYHYVRPTFSKTTQFKLN---GQKPVDEFLEAKELGIHTRPVLLGPVSYLFLG 175 
CaMet6          MVKWFDSNYHYVRPTFSHSTEFKLNTAAGIKPVDEFNEAKALGVQTRPVILGPVSYLYLG 178 
EcMetE          MTKWFNTNYHYMVPEFVKGQQFKLT---WTQLLDEVDEALALGHKVKPVLLGPVTWLWLG 171 
AtMetE          MTKWFDTNYHYIVPELGPEVNFSYA---SHKAVNEYKEAKALGVDTVPVLVGPVSYLLLS 165 
TmMetE          MTKFFNTNYHYLVPEIETEEFYLLE----NKPLEDYLFFKSKGIETAPWVIGPFTFLYLS 157 
                *.*:*::****: * :     :        : :::       * .. * ::**.::* *. 
 
ScMet6          KADKDS-LDLEPLS-LLEQLLPLYTEILSKLASAGATEVQIDEPVLVLDLPANAQAAIKK 233 
CaMet6          KADKDS-LDLEPIS-LLPKILPVYKELLQKLKEAGAEQVQIDEPVLVLDLPEAVQSKFKE 236 
EcMetE          KVKGE---QFDRLS-LLNDILPVYQQVLAELAKRGIEWVQIDEPALVLELPQAWLDAYKP 227 
AtMetE          KAAKGVDKSFELLS-LLPKILPIYKEVITELKAAGATWIQLDEPVLVMDLEGQKLQAFTG 224 
TmMetE          KRNGEWIRRPNQMEKLLESLVSVYKEVFEKLVENGCKEILVNEPAFVCDLEKAHWDLILN 217 
                *         : :. ** .::.:* ::: :*   *   : ::**.:* :*           
 
ScMet6          AYTYFGEQSNLPKITLATYFGTVVPN-LDAIKGLP-VAALHVDFVRAPEQFDEVVAA-IG 290 
CaMet6          AYDALVG-ADVPELILTTYFGDVRPN-LKAIENLP-VAGFHFDFVRVPEQLDEVASI-LK 292 
EcMetE          AYDALQG---QVKLLLTTYFEGVTPN-LDTITALP-VQGLHVDLVHGKDDVAELHKR-LP 281 
AtMetE          AYAELESTLSGLNVLVETYFADIPAEAYKTLTSLKGVTAFGFDLVRGTKTLDLVKAG-FP 283 
TmMetE          VYRELSE----FPLTVFTYYDSVSDY--EACVSLP-VKRLHFDFVSNEENLKNLEKHGFP 270 
                .*  :        : : **:  :     .:   *  *  : .*:*   . .  :    :  
 
ScMet6          NKQTLSVGIVDGRNIWKNDFKKSSAIVNKAIEKLGADRVVVATSSSLLHTPVDLNNETKL 350 
CaMet6          DGQTLSAGVVDGRNIWKTDFAKASAVVQKAIEKVGKDKVVVATSSSLLHTPVDLESETKL 352 
EcMetE          SDWLLSAGLINGRNVWRADLTEKYAQIK---DIVGKRDLWVASSCSLLHSPIDLSVETRL 338 
AtMetE          EGKYLFAGVVDGRNIWANDFAASLSTLQALEGIVGKDKLVVSTSCSLLHTAVDLINETKL 343 
TmMetE          EDKKLVAGVINGRQPWKVDLRKVASLVEK----LGAS--AISNSCPLFHLPVTLELENNL 324 
                .   * .*:::**: *  *:    : ::     :*     ::.*..*:* .: *  *..* 
 
ScMet6          DAEIKGFFSFATQKLDEVVVITKNVSGQDVAAALEANAKSVESRGKSKFIHDAAVKARVA 410 
CaMet6          DAVIKDWFSFATQKLDEVVVIAKNVSGEDVSKQLEANAASIKARSESSITNDPKVQERLT 412 
EcMetE          DAEVKSWFAFALQKCHELALLRDAVNSGDTAALAEWSAP-IQARRHSTRVHNPAVEKRLA 397 
AtMetE          DDEIKSWLAFAAQKVVEVNALAKALAGQKDEALFSANAAALASRRSSPRVTNEGVQKAAA 403 
TmMetE          PGGLKEKLAFAKEKLEELKMLKDFLEG---------KTFDLPNVSFEDFAVDLQAVERVR 375 
                   :*  ::** :*  *:  : . : .         .:  :     .    :  .      
 
ScMet6          SIDEKMSTRAAPFEQRLPEQQKVFNLPLFPTTTIGSFPQTKDIRINRNKFNKGTISAEEY 470 
CaMet6          TINEALATRKAAFPERLTEQKAKYNLPLFPTTTIGSFPQTKDIRINRNKFAKGQITAEEY 472 
EcMetE          AITAQDSQRANVYEVRAEAQRARFKLPAWPTTTIGSFPQTTEIRTLRLDFKKGNLDANNY 457 
AtMetE          ALKGSDHRRATNVSARLDAQQKKLNLPILPTTTIGSFPQTVELRRVRREYKAKKVSEEDY 463 
TmMetE          NLPEDSFRREKEYTERDRIQRERLNLPLFPTTTIGSFPQTPEVRKMRSKYRKGEISKEEY 435 
                 :      *      *   *:   :**  *********** ::*  * .:    :  ::* 
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ScMet6          EKFINSEIEKVIRFQEEIGLDVLVHGEPERNDMVQYFGEQINGYAFTVNGWVQSYGSRYV 530 
CaMet6          EAFINKEIETVVRFQEEIGLDVLVHGEPERNDMVQYFGEQLNGFAFTTNGWVQSYGSRYV 532 
EcMetE          RTGIAEHIKQAIVEQERLGLDVLVHGEAERNDMVEYFGEHLDGFVFTQNGWVQSYGSRCV 517 
AtMetE          VKAIKEEIKKVVDLQEELDIDVLVHGEPERNDMVEYFGEQLSGFAFTANGWVQSYGSRCV 523 
TmMetE          EAFIKEQIKKAIELQEEIGLDVLVHGEFERTDMVEFFAEKLNGIATTQNGWVLSYGSRCY 495 
                   * ..*: .:  **.:.:******* **.***::*.*::.* . * **** *****   
 
ScMet6          RPPIIVGDLSRPKAMSVKESVYAQSITSKPVKGMLTGPITCLRWSFPRDDVDQKTQAMQL 590 
CaMet6          RPPIIVGDVSRPKAMTVKESVYAQSITSKPMKGMLTGPVTILRWSFPRDDVSGKIQALQL 592 
EcMetE          KPPIVIGDISRPAPITVEWAKYAQSLTDKPVKGMLTGPVTILCWSFPREDVSRETIAKQI 577 
AtMetE          KPPVIYGDVSRPKAMTVFWSAMAQSMTSRPMKGMLTGPVTILNWSFVRNDQPRHETCYQI 583 
TmMetE          RPPIIYGTVTRPEPMTLKEITYAQSLTEKPVKGMLTGPVTIMSWSYYREDIPEREIAYQI 555 
                :**:: * ::** .:::     ***:*.:*:*******:* : **: *:*   .  . *: 
 
ScMet6          ALALRDEVNDLEAAGIKVIQVDEPALREGLPLREGTERSAYYTWAAEAFRVATSGVANKT 650 
CaMet6          GLALRDEVNDLEGAGITVIQVDEPAIREGLPLRAGKERSDYLNWAAQSFRVATSGVENST 652 
EcMetE          ALALRDEVADLEAAGIGIIQIDEPALREGLPLRR-SDWDAYLQWGVEAFRINAAVAKDDT 636 
AtMetE          ALAIKDEVEDLEKGGIGVIQIDEAALREGLPLRK-SEHAFYLDWAVHSFRITNCGVQDST 642 
TmMetE          ALAINEEVKDLEEAGIKIVQIDEPAFREKAPIKK-SKWPEYFEWAINAFNLAAN-ARPET 613 
                .**:.:** *** .** ::*:**.*:**  *::  ..   *  *. .:*.:    .  .* 
 
ScMet6          QIHSHFCYSDLDP--NHIKALDADVVSIEFSKKDDANYIAEFKN---YPNHIGLGLFDIH 705 
CaMet6          QIHSHFCYSDLDP--NHIKALDADVVSIEFSKKDDPNYIQEFSE---YPNHIGLGLFDIH 707 
EcMetE          QIHTHMCYCEFNDIMDSIAALDADVITIETSR-SDMELLESFEEFD-YPNEIGPGVYDIH 694 
AtMetE          QIHTHMCYSHFNDIIHSIIDMDADVITIENSR-SDEKLLSVFREGVKYGAGIGPGVYDIH 701 
TmMetE          QIHAHMCYSDFNEIIEYIHQLEFDVISIEASR-SKGEIISAFENFKGWIKQIGVGVWDIH 672 
                ***:*:**..::   . *  :: **::** *: .. : :  * :   :   ** *::*** 
 
ScMet6          SPRIPSKDEFIAKISTILKSYPAEKFWVNPDCGLKTRGWEETRLSLTHMVEAAKYFREQY 765 
CaMet6          SPRIPSKQEFVSRIEEILKVYPASKFWVNPDCGLKTRGWPEVKESLTNMVEAAKEFRAKY 767 
EcMetE          SPNVPSVEWIEALLKKAAKRIPAERLWVNPDCGLKTRGWPETRAALANMVQAAQNLRRG- 753 
AtMetE          SPRIPSSEEIADRVNKMLAVLEQNILWVNPDCGLKTRKYTEVKPALKNMVDAAKLIRSQL 761 
TmMetE          SPAVPSINEMREIVERVLRVLPKELIWINPDCGLKTRNWDEVIPSLRNMVALAKEMREKF 732 
                ** :** : :   :.        . :*:********* : *.  :* :**  *: :*    
 
ScMet6          KN-- 767 
CaMet6          ---- 
EcMetE          ---- 
AtMetE          ASAK 765 
TmMetE          ES-- 734 
 
 
Figure 1.11 (continued).  Amino acid sequences of cobalamin-independent 
methionine synthases. The sequences from S. cerevisiae (ScMet6p), C. albicans 
(CaMet6p), E. coli (EcMetEp), A. thaliana (AtMetEp), and T. maritima 
(TmMetEp) are shown.  The symbols are defined as follows: identical residues 





















Figure 1.12  A ribbon diagram of the structure of cobalamin-independent 
methionine synthase from Arabidopsis thaliana (AtMetEp).  Homocysteine and 
PteGlu5 molecules are depicted as balls and sticks.  The N-terminal domain 
(folate barrel) is in yellow and the C-terminal domain (homocysteine barrel) is in 



















Figure 1.13  A close up view of the AtMetEp active site zinc binding residues.  
The His647, Cys649, and Cys733 residues are represented in the ball and stick 
format, and the side chains are colored according to atom type (nitrogen: blue, 
oxygen: red, carbon: gray and sulfur: yellow).  The active site zinc is represented 
as a green sphere, and water 1 (W1) is represented as a red sphere.  (Ferrer et al, 






















Figure 1.14  A close up view of homocysteine binding in the AtMetEp active site.  



















Figure 1.15  A close up view of 5-CH3-H4PteGlu5 binding in the AtMetEp active 
site.  The pteridine ring forms stacking interactions with Trp567.  The glutamyl 
residue has ionic interactions with the side chain of Arg521 and hydrogen bonds 





The three-dimensional crystal structure of the cobalamin-independent 
methionine synthase from Thermotoga maratima (TmMetEp) was determined by 
Robert Pejchal and Martha Ludwig (Pejchal et al., 2004).  This structure can be 
found in the RCSB Protein Data Bank (http://www.rcsb.org/pdb/) with ID 
numbers 1T7L, 1XDJ, 1XPG, and 1XR2.  TmMetEp is a 734 amino acid enzyme, 
and has a similar structure to AtMetEp (Pejchal et al., 2004).  Residues 1-351 
form the N- terminal folate (βα)8 barrel, and residues 387-734 form the C-terminal 
homocysteine (βα)8 barrel.  A linker joins the two domains with the active site 
formed between the domains (Figure 1.16).  The N-terminal and C-terminal 
domains are similar in structure, and the N-terminal domain is thought to have 
evolved from the C-terminal domain by gene duplication, where the N-terminal 
domain lost the ability to bind zinc and homocysteine (Pejchal et al., 2004).  The 
active site zinc is coordinated to four conserved residues, His618, Cys620, 
Cys704, and Glu642 (Figure 1.17).  The amino group of homocysteine makes 
hydrogen bonds with Asp577, Glu462, and Ile409 (Figure 1.18).  The carboxyl 
group of homocysteine binds to Ser411, and the sulfur coordinates to zinc, at a 
distance of 3.15Å (Figure 1.18).  The pteridine ring of 5-CH3-H4PteGlu3 stacks 
against a conserved Trp539, and makes hydrogen bond interactions with Lys104 
and a water molecule (Figure 1.19).  Glu583 interacts with 2-NH2 and N3 groups 
of the pteridine ring (Figure 1.19).  The first glutamyl residue, of the 
polyglutamate chain of 5-CH3-H4PteGlu3, binds to Arg15, Lys18, Arg493, and 
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Arg496.  The orientation of 5-CH3-H4PteGlu3 is not in an optimal position for the 
transfer of the methyl group to homocysteine, and may indicate that a 
conformational change is needed for catalysis to occur (Pejchal et al., 2004).  The 
methyl faces away from homocysteine, and there is a distance of 11Å between the 
methyl and the sulfur of homocysteine (Pejchal et al., 2004).    
 
 
Figure 1.16  The structure of the Thermotoga maritima MetE protein 
(TmMetEp), in complex with 5-CH3-H4PteGlu3.  The N-terminal domain is in 
yellow, the C-terminal domain is in blue.  Residues 1-351 form the N- terminal 
domain, and residues 387-734 form the C-terminal domain.  The linker that joins 













Figure 1.17  The active site zinc of TmMetEp is coordinated to four residues, 
His618, Cys620, Cys704, and Glu642.  The zinc atom is represented as a green 





















Figure 1.18  The homocysteine binding residues in the TmMetEp active site.  The 
amino group of homocysteine makes hydrogen bonds with Asp577, Glu462, and 
Ile409.  The carboxyl group of homocysteine binds to Ser411, and the sulfur 









Figure 1.19  Binding of the folate substrate in the active site of TmMetEp.  The 
pteridine ring of 5-CH3-H4PteGlu3 stacks against a conserved Trp539, and makes 
hydrogen bond interactions with Lys104.  Glu583 interacts with 2-NH2 and N3 
groups of the pteridine ring.  The first glutamyl residue, of the polyglutamate 
chain of 5-CH3-H4PteGlu3, binds to Arg15, Lys18, Arg493, and Arg496.  (Pejchal 





In both of the cobalamin-independent methionine synthase structures only 
one glutamyl residue is observed, even though the length of the polyglutamate 
chain is critical for enzyme activity (Ferrer et al., 2004; Pejchal et al., 2004).  One 
reason for this is that the polyglutamate chain may not interact with specific 
groups in the active site (Fu et al., 2003).  If the polyglutamate chain occupies 
several different conformations, the electron density will not be clearly resolved.  
Also, the high salt concentrations in the crystal conditions may interfere with the 
binding of the anionic polyglutamate chain to the active site (Fu et al., 2003).   
Proposed Catalytic Mechanisms 
Zinc is often a cofactor in proteins that use thiols as nucleophiles, 
including proteins that transfer methyl groups to thiols (Matthews et al., 1997).  
Both MetHp and MetEp activate the homocysteine upon binding it to zinc 
(Peariso et al., 2001).  Both enzymes must catalyze the transfer of a poor leaving 
group, methyl from 5-CH3-H4PteGlun, to a poor nucleophile, the sulfur of 
homocysteine (Pejchal et al., 2004).  MetHp utilizes cobalamin to facilitate this 
reaction.  MetEp appears to catalyze the direct transfer of the methyl group, from 
5-CH3-H4PteGlun, to the methyl acceptor, homocysteine (Pejchal et al., 2004).  In 
order for the methyl to become a leaving group, 5-CH3-H4PteGlun needs to be 
protonated.  This only occurs when a ternary complex forms, when the MetEp 
binds to 5-CH3-H4PteGlun and homocysteine (Taurog et al., 2006).  Upon binding 
homocysteine alone, the active site zinc binds and converts the thiol to a thiolate, 
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activating homocysteine (Taurog et al., 2006).  In contrast, when MetEp binds 5-
CH3-H4PteGlun, the methyl is pointed away from the zinc and is not protonated.  
However, both these binary complexes are suitable for methyl transfer reactions 
(Taurog et al., 2006).  The rate constants and equilibrium constants have been 
determined for MetEp, and these constants were used to explain the steps in 
substrate binding (Taurog et al., 2006).  The two substrates were found to bind 
synergistically, where the binding of one substrate increases the affinity of the 
other by ~30 fold (Taurog et al., 2006).  So, binding of either 5-CH3-H4PteGlun or 
homocysteine appears to reorganize the active site in favor of binding the other 
substrate (Taurog et al., 2006).   
Both MetHp and MetEp have similar strategies for catalyzing the transfer 
of the methyl group from 5-CH3-H4PteGlun to homocysteine (Taurog et al., 
2006), but the actual mechanisms by which this occurs is different.  In MetHp, 5-
CH3-H4PteGlun and homocysteine bind to separate domains, and cobalamin 
mediates the transfer of the methyl group from 5-CH3-H4PteGlun to 
homocysteine.  MetEp catalyzes the direct transfer of the methyl group from 5-
CH3-H4PteGlun to homocysteine, which requires 5-CH3-H4PteGlun to be in 
proximity to homocysteine.  The significant mechanistic differences between 
MetHp and MetEp make the cobalamin independent methionine synthase an 
intriguing anti-fungal drug target.  A compound consisting of a fusion of both 
substrates can be used as a specific inhibitor for cobalamin-independent 
 30
methionine synthases.  In Saccharomyces cerevisiae, the cobalamin-independent 
methionine synthase gene is labeled MET6 (Csaikl and Csaikl, 1986).  I will refer 
to the S. cerevisiae MET6 gene as ScMET6 in this thesis.  The ScMET6 open 
reading frame (Saccharomyces Genome Database ORF YER091c; 
http://www.yeastgenome.org/) is located on chromosome V of the S. cerevisiae 
genome, and encodes a protein of 767 amino acids.  The MET6 gene is conserved 
in many other fungi, including some pathogens.  The MET6 gene in Candida 
albicans (CaMET6 ORF CA0653; http://genolist.pasteur.fr/CandidaDB/) encodes 
a homologous protein that is 75% identical to that encoded by the ScMET6 gene 
(Fig. 1.11).  Since humans use only cobalamin-dependent methionine synthase 
and all fungi investigated to date, including C. albicans, use only the cobalamin-
independent enzyme, the Met6 protein could be a promising anti-fungal drug 
target. 
Saccharomyces cerevisiae  
Among the many different kinds of yeasts, S. cerevisiae is traditionally 
used for experimentation, and the complete DNA sequence of its genome has 
been determined.  There are three types of S. cerevisiae cells, the a, the α, and the 
a/α.  The a and the α are haploid, and the a/α is diploid.  Both haploid and diploid 
cells can reproduce asexually by budding (Figure 1.20).  When a bud forms and 
nearly reaches the size of the parent cell, the nucleus divides, and the two cells 
separate into the parent cell and the daughter cell (Pringle et al., 1981).  Budding 
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leaves behind a bud scar.  The diploid cells can undergo meiosis and recover the 




Figure 1.20  Asexual Reproduction in Yeast.  A.  Both haploid and diploid yeast 
cells can reproduce through budding.  B. Under starvation conditions, diploid 
yeast cells can undergo meiosis and form haploid ascospores that give rise to 




Haploid S. cerevisiae cells can undergo sexual reproduction, which occurs 
when the a and the α cells mate (Figure 1.21).  The sexual reproduction cycle 
alternates between haploid and diploid yeast cells.  Sexual reproduction begins 
when pheromones are released, and bind to cell surface G-coupled protein 
receptors.  Each cell type responds to the signals by forming a gamete.  When this 
occurs, the cells stop dividing and they elongate to form shmoos (Figure 1.21).  
When shmoos of opposite mating type come into close proximity to each other, 
they fuse to form a zygote.  This fusion results from two shmoos joining together 
at their small ends with a constriction in between.  Each shmoo contains a haploid 
nucleus, and both nuclei come together and fuse to form a diploid a/α nucleus.    
Zygotes are easy to identify when they form the first bud, and they form a diploid 
colony.  Cells of the diploid colony then undergo mitosis.  The next step in the life 
cycle is the conversion of the diploid cell into the ascus, which contains the 
ascospores that are produced through meiosis.  This step marks the transition from 
the diploid phase back to the haploid phase of the life cycle.  The spores are then 
released from the ascus, and the spores germinate to form either a or α haploid 
cells.  
Plasmid DNA containing a gene of interest can be easily transformed into 
yeast cells.  Genes that complement specific auxotrophic strains are used as 
markers to select for the cells that have been successfully transformed.  Some 
common selection markers used are the yeast URA3 gene, LEU2 gene, HIS3 gene, 
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and TRP1 gene, which complement ura3, leu2, his3, and trp1 mutants 
respectively.  Dominant genes are denoted using capitalized italics for all three 
letters, and recessive genes are denoted using lowercase italics for all three letters. 
 
 
Figure 1.21 The yeast life cycle.  The a and the α haploid mating types form 
shmoos, that fuse together to form a diploid zygote.  The zygote forms a bud, and 
divides by mitosis, forming a diploid colony.   An ascus is formed, and spores are 
the result of meiosis.  The ascospores are released, and germinate to form haploid 




Genes can be cloned into yeast vectors using the same approach used for 
E. coli.  CEN plasmids are low copy, autonomously replicating, vectors 
maintained at 1-3 copies per cell.  A CEN plasmid contains a centromere, which 
allows the attachment of the plasmid to the mitotic spindle.  This ensures that the 
plasmid segregates to the mother and daughter cells during the cell cycle.  These 
vectors can be used with any promoter.   
YEp vectors are high copy autonomously replicating vectors and are 
present at 20-50 copies per cell (Burke et al., 2000).  These plasmids have a 2μ 
origin of replication, which allows the plasmids to segregate to the mother and 
daughter cells during mitosis (Figure 1.22).  These plasmids can also be used with 
any promoter.  A high copy vector coupled with a strong promoter can produce an 
abundant amount of protein.  Many yeast vectors also contain an E. coli origin of 












Figure 1.22 Map of the YEp24 yeast expression vector.  This vector has a 2μ 
origin of replication, and URA3 auxotrophic marker.  It also has the bacterial 





C. albicans is genetically very similar to Saccharomyces cerevisiae, and is 
an important model for pathogenic yeast.  However, C. albicans has distinct 
differences, which are thought to be the key to its pathogenicity.  Possibly, the 
two important differences are that C. albicans is asexual and diploid (Whelan et 
al., 1981).  Also, C. albicans has additional morphologies (Figure 1.23), which 
develop under different environmental conditions.  For example, C. albicans is 
one of few Candida species that forms a morphologically distinct type of germ 
tube.  Changes in temperature, changes in pH, immune responses, and an increase 
in C. albicans population trigger production of germ tubes. Germ-tube formation 
can be induced in-vitro by growing the cells in serum, and this is the traditional 
method for identifying C. albicans in clinical samples (Taschdjian et al., 1960).  
Furthermore, C. albicans can reproduce in two different ways.  One way, is to bud 
from yeast cells, and the other way is to branch off into pseudohyphae, which 
eventually break off and form new individuals (Figure 1.23).   
C. albicans is normally present in the natural flora of mammals including 
human beings.  It inhabits mucosal surfaces in the oral cavity, esophagus, vaginal 
cavity, and gastrointestinal tract.  In humans with healthy immune systems 
bacteria present in the normal flora, such as Escherichia coli, Pseudomonas 
aeruginosa, and Lactobacillus acidophilus (Fitzsimmons et al., 1994; Jack et al., 
1990), keep C. albicans growth under control.  In physiologically or medically 
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immunosuppressed patients, or immunocompromised patients C. albicans is able 
to overgrow and cause infection.  In the past two decades, C. albicans has become 
one of the most common opportunistic microorganisms causing nosocomial 
infections.  Patients susceptible to Candia albicans infections include those with 
autoimmune diseases, HIV/AIDS, catheters, pregnancy, antibiotic therapy, 
neutropenia, and solid organ transplants. 
There are two types of C. albicans infections, superficial and invasive.  
Examples of superficial infections include oral and vaginal thrush.  Under 
favorable conditions Candida cells multiply and cause a white build up of cells 
and secretions.  Superficial C. albicans infections are easier to diagnose because 
those areas of the body are readily accessible for testing.  Samples of the infected 
tissue can be taken and tested in the laboratory.  Oral candidiasis can change from 
the superficial oral thrush into the more invasive oropharangeal candidiasis in 
AIDS patients.  This occurs when the disease spreads from the oral cavity to the 
esophagus, creating a severe form of the infection. 
Systemic infections are invasive, and the main source of C. albicans cells 
involved is the gastrointestinal tract.  Overgrowths of cells in the intestine cause 
C. albicans to undergo a morphologic change from yeast cells to hyphae.  If the 
infection is untreated, the hyphae can tunnel through the cellular tissue of the 
gastrointestinal tract and release secreted aspartic proteinases and C. albicans 
yeast cells into the blood stream.  Once in the blood stream, the secreted aspartic 
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proteinases (SAPs) allow C. albicans to invade organs in other parts of the body.  
Some results of systemic infections include invasion of cardiac tissue, kidneys, 
and the brain.   
Systemic infections can be induced in mice, which are very similar to 
those found in humans.  In the mouse model, the main focus of infection is in the 
kidneys. After infecting immunocompromised mice, C. albicans is deposited in 
lungs, liver, spleen and kidney, but only the kidneys become infected.  The 
kidneys are where it is possible for researchers to best follow the course of the 
disease (Molero et al., 1998).  Systemic infections in humans most often occur in 
neutropenic patients.  Neutropenic patients are those that lack the important 
neutrophil immune cells.  Neutrophils are innate phagocytic cells involved in 
killing, release of chemokines and cytokines, and the costimulation in response to 
invading pathogens.  Systemic C. albicans infections are very difficult to 
diagnose, because of the inability to distinguish between normal levels and 
overgrown levels of C. albicans in the body.  This in turn delays treatment, which 
allows the infection to progress and become more severe. 
Once a C. albicans infection has been identified there are drug treatments 
available.  One class of drug used to treat various C. albicans infections is the 
polyene class of anti-fungal agents.  One of the commonly used drugs from this 
class is Amphotericin B (Figure 1.24).  Amphotericin B binds to sterols, 
preferentially ergosterol, and disrupts the osmotic integrity of the fungal 
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membrane (Terrell et. al., 1992).  This disruption causes important components of 
the fungal cell to leak out and the organism dies.  Amphotericin B is an effective 
fungicide, but resistance to this drug is growing rapidly (Nolte et al., 1997).  C. 
albicans becomes resistant to Amphotericin B through a mechanism that allows 
for alteration of the membrane sterols (Nolte et al., 1997).  Resistant C. albicans 
has been shown to have a diminished ergosterol content, and an increase in other 
types of sterols.  For maximum effectiveness, Amphotericin B is used in 
combination with other anti-fungal drugs.  One of these drugs is Fluconazole, 
which belongs to the largest family of anti-fungal agents, the azoles (Figure 1.24).  
Fluconazole binds to the heme iron of cytochrome P450 (Erg11p), and inhibits 
enzymatic reaction (Kelly et al., 1997).  Another target for azoles is the inhibition 
of sterol 14α-demethylase, a cytochrome P450 enzyme that is involved in 
ergosterol biosynthesis (Kelly et al., 1997).  Fluconazole, unlike most other 
azoles, is water soluble, and is a favorite anti-fungal agent.  C. albicans can 
acquire resistance to fluconazole, which is often seen in HIV-patients (Rex et al., 
1995). Increasing drug resistance and severe side effects results in the constant 
























Figure 1.23:  Different morphologies of C. albicans.  (A) C. albicans yeast cells.  
They are similar to S. cerevisiae diploid cells. (B) Germ tube formations extend 
from the yeast cells, and are narrow and uniform. (C) Pseudohyphae are 
elongated, with constrictions at the septa. (D) The hyphal form has parallel walls.  
(Reprinted from Trends in Microbiology, Volume 12, Peter Sudbery, Neil Gow, 
and Judith Berman, The Distinct Morphogenic States of Candida albicans, Pages 
















Experimentation in Candida albicans 
C. albicans is a major model for pathogenic yeast.  C. albicans gene 
functions can be assessed by complementation of S. cerevisiae mutants, although 
study in C. albicans is preferable.  The C. albicans genome is difficult to 
manipulate due to its diploid nature, and the lack of a complete sexual cycle for 
use in experimental manipulations (Molero et al., 1998).  In recent years there 
have been many advancements in transformation, gene expression, and gene 
disruptions for C. albicans.  These tools, along with the complete genome 
sequence of C. albicans, have allowed for rapid identification of essential genes.  
Gene disruption methods rely on the ability to transform with DNA, and the 
integration of that DNA into the C. albicans genome through homologous 
recombination, which occurs frequently in C. albicans.  This allowed for 
auxotrophic mutants to be created and used as hosts for transformation 
experiments.  These auxotrophs include strains with the following mutations:  
ura3, ade2, leu2, his1, arg4, and arg5, 6 (Calderone et al., 2002).  The ability to 
test for essential genes allows the validation of potential anti-fungal drug targets. 
  
Project Goals 
In this study, methionine synthases from C. albicans (CaMET6p) and S. 
cerevisiae (ScMET6p) were investigated.  This ongoing project is a collaborative 
effort with Appling laboratory (The University of Texas at Austin).  The initial 
experiments began when Bert Vick, a technician from the Appling laboratory, 
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cloned ScMET6, including the native ScMET6 promoter into the YEp24 yeast 
shuttle vector (Suliman et al., 2005).  The ScMet6p was expressed in the S. 
cerevisiae cell strain DAY4.1 (a ser1 ura3-52 trp1 leu2).  Susan Dubrowski, an 
undergraduate student from the Appling laboratory, constructed the SDYα Scmet6 
mutant strain (Suliman et al., 2005).  The pEGKT construct containing the 
ScMET6 promoter was created in the Robertus laboratory (The University of 
Texas at Austin), in which I worked. 
The focus of my study was to clone, express and purify CaMet6p, and to 
express and purify ScMet6p.  The kinetic parameters and the requirement for 
polyglutamylated 5-methyltetrahydrofolate were explored using the purified 
protein.  A goal of this work was to implement a strategy for the study of site-
directed mutants.  Apart from the recombinant protein, preliminary experiments to 
study CaMET6 in C. albicans were performed.  A conditional cobalamin-
independent methionine synthase (CaMET6) mutant in C. albicans was 
constructed, using the PCR-based gene disruption method, to assess the viability 
of the resulting null mutant strain.  The results from these experiments have 
provided insights into enzyme function, and support the study of CaMet6p as an 




CHAPTER 2:  MATERIALS AND METHODS 
MATERIALS 
The pre-packed heparin column and the DEAE Sepharose beads were 
obtained from Pharmacia Biotech (Piscataway, NJ). PteroylGlun was obtained 
from Schirck’s Laboratories (Jona, Switzerland). Pb(NO3)2 was obtained from 
Mallinkrodt. L-Homocysteine thiolactone was obtained from Sigma Chemical (St. 
Louis, MO).  The yeast expression vector YEp24 was obtained from Dr. Makkuni 
Jayaram and genomic C. albicans DNA was obtained from Dr. Paul J. Szaniszlo 
(both at The University of Texas at Austin).  All chemicals and reagents were of 
high quality and were stored as per the recommendations of the manufacturer.  
Other specific materials and their sources are provided in the methods section and 
in Appendix A. 
METHODS 
EXPRESSION OF ScMET6p 
YEp-ScMET6 was transformed into the Saccharomyces cerevisiae strain 
DAY4.1 (a ser1 ura3-52 trp1 leu2) using the lithium acetate method (Gietz and 
Woods, 2002).  The DAY4.1 cell strain is auxotrophic for serine, uracil, 
tryptophan, and leucine.  The YEp24 expression vector has a URA3 selection 
marker, selecting for the ability to grow in media without uracil supplementation.  
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Transformed cells were grown in synthetic minimal medium (YMD) containing 
0.7% yeast nitrogen base without amino acids (Difco Bacto®) and 2% glucose, 
supplemented with the following amino acids:  L-serine (375 mg/L), L-leucine (30 
mg/L), L-tryptophan (20 mg/L).  The media, and all glucose and amino acid 
stocks, were made with the highest purity of deionized, distilled water available, 
to allow the yeast cells to grow optimally.  The cell cultures were batch-grown at 
30°C in a rotary shaker.  Three liters of culture were grown at a time, each liter 
grown in a 2.8 L pyrex flask.  When the cultures reached late log phase, 3-4 
OD600, they were harvested in 500 ml centrifuge tubes at 5000 x g for 10 minutes. 
Cloning and Expression of the C. albicans MET6 gene. 
The C. albicans MET6 gene (CandidaDB; 
http://genolist.pasteur.fr/CandidaDB/) was obtained from the C. albicans genome 
by high-fidelity PCR using primers with the sequences 5'-
ATATCAAAAATGGTTCAATCTTCCGTC-3' [CaMET65’; overlap with 
ScMET6SOE primer (below) is in bold and the start codon of MET6 orf is 
underlined] and 5'-CGACGGCATGCGTCTCCAAATTAATCAC-3' 
(CaMET63’; SphI site is underlined).  The amplified fragment started 1 bp 
upstream of the AUG start codon and ended 187 bp after the stop codon, to 
include the poly adenylation sequence.  Splice-overlap extension (SOE) PCR 
(Horton et al., 1993) was used to precisely replace the S. cerevisiae MET6 ORF in 
YEp-ScMET6 with the C. albicans MET6 ORF (Figure 2.1).  The S. cerevisiae 
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MET6 promoter region (592 bp) was amplified from YEp-ScMET6 using primers 
ScMET65’ and ScMET6SOE (5’-TGAACCATTTTTGATATGTACTTTGA-3’; 
overlap with CaMET65’ primer is in bold).  This fragment was joined with the C. 
albicans MET6 ORF amplified fragment (1:1 ratio) in a second PCR using 
primers ScMET65’ and CaMET63’.  The spliced amplified fragment was digested 
with SphI and cloned into YEp24 as before.  The insert was completely sequenced 
to ensure no PCR-induced mutations had occurred.  This construct, YEp-
CaMET6, has the same orientation as YEp-ScMET6, and the C. albicans MET6 
ORF was transcribed using the S. cerevisiae MET6 promoter.  For expression and 
purification of the C. albicans Met6 gene product in S. cerevisiae, YEp-CaMET6 
was transformed into the met6 disruptant strain SDYα, which allowed selection 
for the ability of transformants to grow without methionine supplementation.  
Transformed cells were batch-grown in YMD supplemented with L-serine, L-
leucine, L-tryptophan, and L-histidine (20 mg/L) at 30°C in a rotary shaker and 











Figure 2.1: Splicing by overlap extension using polymerase chain reaction 
(PCR).  In the first step, the ScMET6 promoter is amplified from plasmid DNA 
using primers a and b, and the CaMET6 gene is amplified from genomic DNA 
using primers c and d.  Primers b and c contain sequences that will allow the two 
PCR products to overlap and bind to each other.  In the Second step, the promoter 
and the gene are combined in a final PCR to produce the final product.  (Adapted 







Purification of ScMet6p and CaMet6p 
 
The purification protocols for ScMet6p and CaMet6p were modified from 
the purification reported by Burton and Sakami (1969). The following first three 
steps were used in purifying both ScMet6p and CaMet6p. 
 Step 1.  Transformed S. cerevisiae cells were grown in three liters of 
minimal medium and were harvested at 3-4 OD600 by chilling and centrifuging at 
4000 x g for 5 min.  The cell pellet was suspended in 0.05 M KPO4/pH 7 buffer (2 
ml/gram wet weight of pellet).  Four passes through a 20K French Press cell at 
1000 psi disrupted the suspended cells.  The broken cell suspension was 
centrifuged at 20,000 x g, at 4°C, for 1 hour to remove cell debris and unbroken 
cells.   
 Step 2.  The supernatant was heated to 55°C, and kept at that temperature 
for 5 min.  The solution was cooled rapidly to below 10°C in an ice bucket.  The 
solution was then centrifuged at 8000 x g and 4°C for 10 min. to remove 
denatured protein.  The supernatant solution was collected for further purification. 
 Step3.  The solution pH was reduced to pH 4.5 by adding glacial acetic 
acid, and immediately centrifuged at 10,000 x g, at 4°C, for 10 min.  The pellet 
was discarded, and the supernatant brought to pH 7.0 using 2M KOH. 
 Step4.  ScMet6p was further purified using a 5 ml pre-packed HiTrap 
heparin column (Amersham Pharmacia Biotech.).  The column was washed with 
0.02 M KPO4, pH 7.4, buffer.  The enzyme solution was then applied to a heparin 
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column, and the column was washed with 10 ml 0.02 M KPO4, pH 7.4 buffer.  
The enzyme was eluted using a linear gradient prepared from 25 ml 0.02 M 
KPO4, pH7.4 buffer, and 25 ml 0.02 M KPO4/1.5 M KCl buffer at pH 7.4. 
 CaMet6p was further purified using a 35 ml DEAE Sepharose column.  
The column was washed with 0.02 M KPO4, pH 7.4 buffer.  The enzyme solution 
was then applied to the column, and the column was washed with 70 ml of 0.02 M 
KPO4, pH 7.4 buffer.  The enzyme was eluted using a linear gradient prepared 
from 150 ml 0.02 M KPO4, pH7.4 buffer and 150 ml 0.02M KPO4/1.5 M KCl 
buffer at pH 7.4. 
ENZYME ASSAY 
The enzyme assay was performed using a modification of the procedure 
described by Drummond et al. (1995).  Standard 400 µl reaction mixtures 
contained 50 mM potassium phosphate (pH 7.2), 50 mM Tris-Cl (pH 7.2), 100 
µM MgSO4, 10 mM dithiothreitol, 2 mM L-homocysteine, 66 µM (6R,S)5-CH3-
H4PteGlun, and 9 µg (263 nM) of enzyme.  The reactions were preincubated at 
37°C for 5 minutes, then initiated by the addition of 50 µl of enzyme, and 
terminated after 10 min by the addition of 100 µl of 5N HCl/60% formic acid.  
The reactions were then incubated at 80°C for 10 min, followed by brief 
centrifugation to pellet any precipitated protein.  The methenyl derivative of the 
H4-PteGlun product was quantified spectroscopically at an absorbance of 350 nm, 
using an extinction coefficient of 26,500 M-1cm-1.  The Km values for 5-CH3-
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H4PteGlun were determined from 6 different substrate concentrations within the 
range of 0-500 µM, at saturating L-homocysteine concentration (2 mM).  The Km 
values of L-homocysteine were determined from 6 different concentrations within 
the range of 0-200 µM, at saturating (6R,S)CH3-H4PteGlun concentration (500 
μM).  Initial velocity data were fitted to the Michaelis-Menten equation using 
non-linear regression in the program SigmaPlot (Systat Software, Inc. Point 
Richmond, CA). 
SYNTHESIS OF (6R,S)5-CH3-H4-PTEGLUN FROM PTEGLUN 
 (6R,S)-5-CH3-H4PteGlun was synthesized from PteGlun (Schirck’s 
Laboratories Jona, Switzerland) by a modification of the procedure of Yeo and 
Wagner (1992).  200 μl of 265 μM Pb(NO3)2 was added to 40 μmol of PteGlun, 
and then dissolved by adjusting the pH of the solution to 7.5 using a 5 M NaOH 
solution, and vortexing.  PteGlun was then reduced to H4PteGlun by adding 132 
μmol NaBH4, at 4oC while stirring. Once all of the NaBH4 is added, the solution 
was moved to room temperature and stirred at maximum speed, in the dark and 
under N2, for 2 hours.  The excess NaBH4 was destroyed by cooling the solution 
to 4oC, and lowering the pH to 5.0, by adding 5 M acetic acid.  The pH was then 
adjusted to 7.8 using 5 M NaOH. 
To synthesize CH2-H4PteGlun, H4PteGlun was condensed with 80 μmol of 
37% formaldehyde at 45oC for 15 minutes, in the dark.  CH2-H4PteGlun was then 
 51
reduced to 5-CH3-H4PteGlun using NaBH4.  Ten mg of NaBH4 (264 μmol) was 
added to 50 μl of ddH2O, and 10 μl of this solution was added to the tube 5 times 
over 20 minutes.  The pH was maintained by adding 2-5 μl of 20% (w/v) citric 
acid per addition of NaBH4.  Once all of the NaBH4 was added, the tube was 
flushed with N2 and incubated at 45οC for 60 minutes in the dark.  After this 
mixture was cooled to 4oC, 2-mercaptoethanol was added to a final concentration 
of 50 mM.  The pH of the solution was then adjusted to 5.0 with 5 M acetic acid 
to destroy any excess NaBH4, and was vortexed until there was no more 
bubbling.  The pH was finally brought back to 7.5 using 5 M NaOH.  The final 
product, was confirmed to be 5-CH3-H4PteGlun, by checking the spectrum of a 10-
4 dilution.   
To determine the purity and yield of the 5-CH3-H4PteGlun, 2 μl of the 
product were diluted into 200 μl 10 mM Tris-Cl pH 7.5.  10 μl of the dilution was 
added into 400 μl of 10 mM Tris-Cl pH 7.5.  100 μl of 5 M HCl/60% formate was 
added, and mixture was heated 80oC for 10 minutes.  After cooling, the solution 
to room temperature, the spectrum was read.  A peak at 350 nm is diagnostic of 
H4-PteGlun, and the lack of a peak indicates 5-CH3-H4-PteGlun.  The (6R,S)5-
CH3-H4-PteGlun was stored under N2 in dark at –20oC. 
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SYNTHESIS OF L-HOMOCYSTEINE FROM L-HOMOCYSTEINE THIOLACTONE  
 L-homocysteine was prepared from L-homocysteine thiolactone by 
alkaline hydrolysis (Drummond et al., 1995).  Fifty mg of L-homocysteine 
thiolactone (Sigma) was dissolved in 1.7 ml ddH2O that had been bubbled with 
nitrogen to removed dissolved oxygen.  Alkaline hydrolysis was initiated by 
adding 0.83 ml of nitrogen-bubbled 800 mM NaOH solution.  The reaction was 
flushed with nitrogen and incubated at 45oC for 6 minutes.  The reaction was 
terminated when the pH of the reaction solution was adjusted to pH 5.0 using 5.0 
M acetic acid; L-homocysteine is stable at pH 5.0.  The concentration of L-
homocysteine was determined by titration with 5,5’-dithiobis-2-nitrobenzoic acid 
(DTNB), and aliquots of 100 mM concentration were stored at -80oC.   
SITE-DIRECTED MUTAGENESIS 
 The CaMET6 derived amino acid sequence was compared with the 
sequences of T. maritima and A. thaliana, for which x-ray structures exist, and a 
model of the CaMet6 protein was created (Figure 2.2).  The comparison suggested 
residues that might participate in homocysteine binding.  Two carboxylates were 
likely to pair with the amine group of homocysteine, Glu 499 and Asp614 (Figure 
2.3).  Asp614 in CaMet6p is homologous to Asp577 from T. maritima and 
Asp605 from A. thaliana.   Therefore the following point mutations were made in 
the CaMET6 gene sequence:   
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D614N Asp614 to Asn614 
D614A Asp614 to Ala614 
Site-directed mutagenesis was performed using a modification of the method 
based on the Quik Change® Site Directed Mutagenesis Kit (Stratagene, La Jolla, 
CA).  Using this protocol two complimentary, overlapping oligonucleotides were 
synthesized.  These oligonucleotides were about 30 bp long and contain the 
desired mutation flanked by unmodified nucleotide sequence.  A 50 μl PCR 
reaction was assembled using 250 ng of each oligonucleotide, combined with 
either 40 or 80 ng of methylated, dsDNA template, and the appropriate amount of 
dNTPs, Pfu polymerase, and 10X reaction buffer.  After the reaction, the mixture 
was then digested with Dpn I, to remove all the non-mutated template plasmid.  
The mutated DNA was transformed into E. coli competent cells.  To determine if 
the desired mutations were obtained, the plasmid DNA was purified from the E. 












Figure 2.2  The sequence of CaMet6p was modeled on the structure of AtMetEp.  












































Figure 2.3 Modeled structure of the CaMet6 protein, and the bound homocysteine 
(HCY) is shown in orange.  The Glu499 and the Asp614 are potentially important 







5’ FLUOROOROTIC ACID 
 The SDYα cell strain contains the ScMET6 gene disrupted by a URA3 
cassette (Suliman, 2005).  In order to use the URA3 selection marker for other 
yeast expression vectors, while maintaining the met6 mutation in the SDYα cell 
strain, the URA3 cassette needed to be evicted.  This was accomplished using 5-
fluoroorotic acid (5-FOA) as a selective agent (Boeke et al., 1984; Boeke et al., 
1987).  The URA3 gene codes for the enzyme, orotidine-5'-monophosphate 
decarboxylase, and acts in the last step of uracil biosynthesis.  Orotidine-5'-
monophosphate decarboxylase cannot distinguish between 5-FOA and its natural 
substrate, orotic acid, and therefore uses 5-FOA to make the toxic product 5-
fluorouracil.  Only cells lacking a functional URA3 gene will grow on 5-FOA 
plates, because they will not be able to make the toxic product, and the cells will 
not die. 
 5-FOA agar plates were made by using the following recipe for minimal 
media:  6.7% yeast nitrogen base without amino acids, 2% glucose, 5-FOA (1.0 
g/L), uracil (50 mg/L), L-serine (375 mg/L), L-leucine (30 mg/L), L-tryptophan 
(20 mg/L), L-methionine (20 mg/L), and L-histidine (20 mg/L).  The uracil was 
needed to supplement the mutated strains.  One hundred μl of SDYα cells from an 
overnight culture grown in YPD liquid media were plated on the 5-FOA plates.  
Colonies appeared within 4-7 days at 30oC.  The resulting colonies were tested for 
the lack of growth in the absence of uracil, and they were also tested for lack of 
 57
growth in the absence of methionine and in the presence of uracil.  The resulting 
strain was labeled HSYα (α ser1 ura3-52 trp1 leu2 his4 met6).  
Construction of the GST fusion CaMet6p  
 
 The pEGKT vector was constructed for the galactose inducible 
overexpression of glutathione S-transferase (GST) fusion proteins in yeast 
(Mitchell et al., 1993).  Because the GAL1-10 upstream activation sequence 
(UAS) was not successfully removed from the pEGKT vector, it consequently 
repressed the ScMET6 promoter (Figure 2.4).  Therefore, the ScMET6 promoter-
GST fragment was digested from pEGKT using XhoI and XmaI.  XmaI is an 
isoschizomer of SmaI, meaning both restriction enzymes recognize the same 
sequence.  XmaI was used instead of SmaI because it produces a 5’ extension, 
whereas SmaI produces blunt-ended fragments.  The ScMET6 promoter-GST 
fragment was then ligated into the XhoI and XmaI restriction sites on the pRS424 
vector, which was obtained from the Arlen Johnson laboratory (University of 
Texas at Austin).  The CaMET6 gene was cloned into the XmaI restriction site 
(Figure 2.5).  The following primers were used for amplification of the CaMET6 
gene: 5'-ATTACCCGGGATGGTTCAATCTTCCGTC-3' and 5'-
CGACGCCCGGGGTCTCCAAATTAATCAC-3'  (the XmaI restriction site is 
underlined).  The PCR was carried out as described earlier for cloning of 
CaMET6 into YEp24.  This construct was sequenced to ensure no mutations 
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occurred, and to ensure that the CaMET6 gene was in frame with the GST.  The 
fusion protein was expressed in the SDYα cell strain, and purified using 10 ml of 
glutathione agarose beads.  The supernatant of the lysed cells was incubated at 
4oC with shaking overnight, in a 50 ml conical tube.  The mixture is then loaded 
on a column, and washed for three hours with 20 mM KPO4/10 mM BME pH 7.4.  
Then the fusion protein was eluted using 200 ml of 10 mM reduced glutathione in 






















Figure 2.5 A map of the ScMET6 promoter and GST construct.
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Gene Deletion of CaMET6 
The C. albicans strain BWP17 (ura3Δ::λimm434/ura3Δ::λimm434 
his1::hisG/his1::hisG arg4::hisG/arg4::hisG), and the plasmids pGEM-URA3 
and pRS-ARG4 were generously provided by Dr. Aaron Mitchell (Wilson, 1999).  
The plasmid pURA3-PGAL1-GFP was obtained from Dr. Judith Berman 
(Gerami-Nejad, 2004).  Cultures were grown at 30°C in YPD + Uri for routine 
nonselective growth, or YM medium for selective growth.  YPD + Uri medium 
consisted of 10 g yeast extract, 20 g peptone, 20 g glucose, and 80 mg of uridine 
per liter.  YM medium consisted of 6.7 g yeast nitrogen base without amino acids 
and 20 g glucose, and was supplemented with the necessary auxotrophic 
requirements including: 80 mg/L uridine, 20 mg/L L-histidine, 20 mg/L L-
methionine, and 40 mg/L L-arginine.  To induce the GAL1 promoter, 20 g 
glucose was replaced with 20 g raffinose and 20 g galactose.   Agar plates 
contained 20 g/L agar. 
To assess the importance of the cobalamin-independent methionine 
synthase gene in a C. albicans strain, gene deletion experiments were performed 
using the BWP17 strain.  This strain is auxotrophic for uridine, histidine, and 
arginine.  The PCR-based gene disruption method (Wilson, 1999) was used to 
attempt to create a homozygous CaMET6 deletion mutant strain.  Different 
selectable markers are used to disrupt each allele, so that each deletion could be 
tracked (Kurtz et al., 1989; Negredo et al., 1997; Wilson et al., 1999).    The 80-
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mer primers used are listed in Table 2.1.  The CaMET6-5DR and CaMET6-3DR 
primers were designed so that 20 nucleotides from each bind to both pRS-ARG4 
and pGEM-URA3 plasmids, amplifying an ARG4 and a URA3 cassette 
respectively.  The remaining 60 nucleotides are homologous to the sequences that 
flank the CaMET6 open reading frame (ORF).  The deletion cassettes were 
amplified in PCR reactions containing 4 μl of 10-4 diluted plasmid stock (Qiagen) 
of pGEM-URA3 or pRS-ARG4ΔspeI, 4 μl of a 10 μM stock of each primer 
(CaMET6-5DR and CaMET6-3DR), 10 μl of KOD polymerase 10X PCR buffer 
(Novagen), 4 μl of a mixture of 10 mM dNTPs, 6 μl of 25 mM MgCl2, 67 μl 
deionized H2O, and 1 μl KOD Hot Start DNA polymerase (Novagen).  The 
mixture was incubated at 94˚C for 5 min, followed by 30 cycles of 94˚C for 45 
sec, 50˚C for 1 min, and 72˚C for 3 min.  After a final extension at 72˚C for 8 
min, the samples were incubated at 4˚C until the samples were retrieved.  The 
PCRs were checked by fractionating 5 μl of each sample on a 0.8% agarose gel.  
The remainder of each reaction was ethanol precipitated and resuspended in 5 μl 
of TE buffer (10 mM Tris HCl pH 7.5, 1 mM EDTA pH 8.0), without further 
purification.  To prepare the samples for transformation, 10 μl of 10 mg/ml 
herring-testes DNA (Sigma) is added to the PCR products. 
Overnight cultures of BWP17 were diluted 100 fold in 50 ml of YPD + 
uridine media, and incubated at 30oC, with shaking for four generations 
(approximately 6 hours).  Cells were pelleted and washed with 5 ml sterile water, 
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and suspended in 0.5 ml TELiOAc (10 mM Tris-HCl pH 7.5, 1 mM EDTA pH 
8.0, and 100 mM lithium acetate).  100 μl aliquots of cell suspension were 
dispensed into microcentrifuge tubes containing PCR product and herring-testes 
DNA, and incubated at room temperature for 30 minutes.  Then, 0.7 ml of PLATE 
buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0, 100 mM lithium acetate, 
40% polyethylene glycol 3350) was added to each tube, mixed by inversion, and 
incubated at room temperature overnight (approximately 16 hours).  The next day, 
the mixtures were heat shocked for 1 hour at 42˚C.  Cells were pelleted in a 
microcentrifuge for 30 seconds, suspended in 1 ml of sterile water, and plated on 













Table 2.1 Primer sequences 
Primer Sequence 5’-3’ Purpose 
CaMET6-5DRa TTGTTAAGATTTTATCTACAAATCAAAAACTTTTTATATCCCCCCCCATTATAATCAACAT
GTGGAATTGTGAGCGGATA 
Deletion of CaMET6. 
CaMET6-3DRa TCAACATTTCAAGAATTGAAAATGCAAAATAAATCAATGAATGCTTTGAATCATAAAAG
ATTTCCCAGTCACGACGTT 
Deletion of CaMET6. 
GAL1-5DRb CCTTTTTCTTATTCTTCTTCTAATTTTGTTAAGATTTTATCTACAAATCAAAAACTTTTTAT
ATCCCCCCTCTAGAAGGACCACCTTTGATTG 
GAL1 promoter introduction. 
GAL1-3DRb GTAGGCCTCAGTGATTTTTTTTAATTCTCTTTGACCACCAATACGTGGGAAACCTAAGACG
GAAGATTGAACCATTTTAATAAACGCGGATCC 
GAL1 promoter introduction. 
FL-5DR TATCCCCCCCTATTCTGAAA Detection of disrupted alleles. 
FL-3DR GTCGTCATAAAACATAAAAAAGAAA Detection of disrupted alleles. 
ARG4-1012-5DR CCATTATTTGATGCATTGAC Detection of disrupted alleles. 
URA3-517-5DR GTTGAAATTGCTAAATCCG Detection of disrupted alleles. 
a Boldface sequences in CaMET6-5DR and CaMET6-3DR primers are segments that anneal to plasmids pGEM-
URA3 and pRS-ARG4ΔSpeI for amplification of the URA3 and ARG4 deletion cassettes.  b Boldface sequences in 
GAL1-5DR and GAL1-3DR primers are segments that anneal to plasmid pURA3-PGAL1-GFP for amplification of  
the PGAL1 cassette. 
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GENOMIC DNA ISOLATION AND IDENTIFICATION OF INTEGRATION EVENTS 
To determine if the integration events were successful, genomic DNA was 
isolated from the transformants.  Overnight cultures in 3 ml selective media, were 
grown and the cells were spun down in a microcentrifuge, for 5 minutes.  The 
cells are washed in 1.0 ml sterile water, and the cells were suspended vigorously 
in 0.4 ml TENTS (10 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0, 100 mM NaCl, 
2% Triton X-100, 1% Sodium Dodecyl Sulfate).  The cells were vortexed for 2 
minutes, after 0.2 ml of 0.45 mm glass beads and 0.4 mL phenol-chloroform were 
added.  The tubes were then spun for ten minutes at maximum speed.  The upper 
aqueous layer was pippetted into a new tube, and 1 ml of ethanol was added.  All 
of the nucleic acid was precipitated by inverting the tube 5-10 times, and was 
pelleted in a microcentrifuge at 4˚C for 5 minutes.  The pellet was dissolved in 
200 μl of TE containing 10 μg/ml RNAse A, and incubated at room temperature 
for 30 minutes.  The DNA was then ethanol-precipitated, and dissolved in 100 μl 
TE on ice for 1 hour.  The genomic DNA samples were then screened using PCR.  
The genomic DNA from the URA3 cassette transformations was screened using 
the FL-5DR and FL-3DR primers, which annealed to the target gene locus outside 
of the altered region.  The genomic DNA from the ARG4 cassette transformations 
was screened using the ARG-4-1020-5DR primer, which annealed within the 
ARG4 cassette, and FL-3DR primer, which annealed outside of the altered region.  
Each PCR mixture contained 2 μl of genomic DNA, 5 μl 10X PCR buffer 
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(Novagen), 3 μl 25 mM MgCl2 (Novagen), 2 μl 10 mM dNTPs, 1 μl 10 μM of 
each primer, and 1 μl KOD Hot Start DNA Polymerase (Novagen).  The reactions 
were incubated at 94˚C for 5 minutes, followed by 30 cycles of 94˚C for 1 minute, 
50˚C for 1 minute, and 72˚C for 3 minutes.  After a final extension at 72˚C for 8 
minutes, the samples were fractionated on a 0.8% agarose gel.   
CONSTRUCTION OF THE CONDITIONAL CaMET6 MUTANT 
The Berman Laboratory created plasmids containing cassettes for PCR-
mediated construction of regulatable genes (Gerami-Nejad, 2004).  The plasmid 
pURA3-PGAL1-GFP contains a cassette composed of a URA3 selection marker, a 
GAL1 regulatable promoter, and a GFP gene.  For our experiments the GFP tag 
was not needed, and only the portion of the cassette that contains the URA3 
selection marker and the GAL1 regulatable promoter was used; this cassette was 
labeled PGAL1.  To integrate PGAL1 upstream of CaMET6, a forward primer was 
designed to include 70 nucleotides from the sequence immediately upstream of –
15 from the CaMET6 start codon, and 23 nucleotides that bind on the PGAL1 
cassette (GAL1-5DR, Table 2.1).  The reverse primer was designed to include the 
reverse complement of nucleotides 1-74 of the CaMET6 ORF, and the reverse 
compliment of 18 nucleotides that bind on the PGAL1 cassette (GAL1-3DR, Table 
2.1).  The PGAL1 cassette was amplified in PCRs containing 1 μl of 200 ng/μl stock 
of plasmid pURA3-PGAL1-GFP, 4 μl of 10 μM stock of each primer (GAL1-
5DR and GAL1-3DR), 10 μl of KOD polymerase 10X PCR buffer (Novagen), 4 
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μl of a mixture of 10 mM dNTPs, 12 μl of 25 mM MgCl2, 20 μl of 1 mg/ml BSA 
stock, 44 μL deionized H2O, and 1 μL KOD Hot Start DNA polymerase 
(Novagen).  The mixture was incubated at 94˚C for 5 minutes, followed by 30 
cycles of 94˚C for 45 seconds, 50˚C for 1 minute, and 68˚C for 3 minutes.  After a 
final extension at 68˚C for 8 minutes, the samples were incubated at 4˚C until the 
samples were retrieved.  The PCRs were checked by fractionating 5 μl of each 
sample on a 0.8% agarose gel.  The remainder of each reaction was ethanol-
precipitated and resuspended in 5 μl of TE buffer (10 mM Tris HCl pH 7.5, 1 mM 
EDTA pH 8.0), without further purification.  Ten of the samples were combined 
and transformed into the heterozygous CaMET6/Camet6 mutant that was 
disrupted with the ARG4 selection marker.  The genomic DNA from the 
transformants was screened using the ARG4-1020-5’ primer, which annealed 
within the ARG4 cassette, and the FL-3DR primer, which annealed outside of the 
altered region, to test for the presence of the ARG4 cassette.  The transformants 
were also screened using the URA3-517-5DR, which annealed within the URA3 
portion of the PGAL1 cassette, and the FL-5DR primer, which annealed outside of 
the altered region, to test for the presence of the PGAL1 cassette.  Further screening 
reactions were set up with the FL-5DR and FL-3DR, which both anneal outside 
the altered region. 
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CaMet6p POLYCLONAL ANTIBODIES 
The CaMet6 protein was purified as previously described in the materials 
and methods section.  A 5 ml sample of CaMet6p, at a concentration of 2 mg/ml, 
was sent to The University of Texas MD Anderson Cancer Center Department of 
Veterinary Sciences (Bastrop, TX).  Polyclonal antibodies were raised against 
CaMet6p in two male rabbits.  The immune serum was used in Western Blot 
experiments.  
SDS-PAGE AND WESTERN BLOTTING 
 C. albicans strains were grown under inducing and repressing conditions 
to an A600 of 1, and spun down in a centrifuge for 5 minutes at 5000 x g.  The cell 
pellets were resuspended in 2 ml/gram wet weight of 50 mM KPO4/ 10 mM 
BME/1 mM phenylmethylsulfonyl fluoride, pH 7.0.  The cells were broken open 
using 450 μm glass beads (Sigma), and the cell debris was pelleted in a tabletop 
centrifuge.  The protein concentrations in the whole cell lysates were estimated 
using absorbance at 280 nm.  Equal amounts of protein from each of the samples 
were loaded on an 8% SDS-polyacrylamide gel, and SDS-polyacrylamide gel 
electrophoresis was performed according to Laemmli (Laemmli, 1970).  The 
protein samples were transferred to a PVDF membrane (Millipore) using the Bio-
Rad semi-dry blotter apparatus at 100 mA for 20 minutes, and the membrane was 
blocked with 5% non-fat milk.  The primary antibody, polyclonal anti-CaMet6p, 
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was diluted to 1:1000, and the secondary antibody, goat anti-rabbit horseradish 
peroxidase conjugate (Bio-Rad), was diluted to 1:2000.  CaMet6p was detected 
by chemiluminescence, using the SuperSignal West Pico Chemiluminescent 
Substrate (Pierce). 
GROWTH ASSAYS 
Overnight cultures of BWP17 were grown to logarithmic phase at 30˚C in 
YPD + uridine media, and inoculated in YM media containing 2 % glucose, 20 
mg/L L-histidine, 40 mg/L L-arginine, and 80 mg/L uridine.  Overnight cultures 
of the conditional CaMET6 mutant were grown to logarithmic phase at 30 ˚C in 
YM media containing 2% glucose, 20 mg/L L-histidine and 20 mg/L L-
methionine, and inoculated in YM media containing 2% glucose and 20 mg/L L-
histidine.  Both strains had a starting OD600 of 0.09, and were assayed under three 
concentrations of L-methionine; 10 μM, 25 μM, and 50 μM.  These 
concentrations mimic serum levels in humans.  The cultures were grown in 








CHAPTER 3:  RESULTS 
EXPRESSION OF THE MET6 GENES 
 The YEp24-ScMET6 construct was expressed in the Day4.1 
Saccharomyces cerevisiae cell strain.  YEp-CaMET6 was expressed in the met6 
mutant of S. cerevisiae cell strain, SDYα.  The SDYα cell strain is a strict 
methionine auxotroph, and is not viable without the addition of methionine 
(Figure 3.1).  The SDYα strain has no detectable methionine synthase activity, 
and was complemented by the YEp24 vector expressing the ScMET6 gene under 
the control the ScMET6 native promoter.  The CaMET6 gene also complemented 





































Figure 3.1:  Complementation of S. cerevisiae ∆met6 mutant.  SDYα (∆met6) 
(1), Day4.1 transformed with YEp24 (wt control) (2), SDYα transformed with 
YEp24-ScMET6 (3), and SDYα transformed with YEp24-CaMET6 (4).  Plates 
contain yeast minimal medium supplemented with histidine, leucine, tryptophan, 




PURIFICATION OF CaMET6 AND ScMET6 PROTEINS 
 The ScMET6 promoter is among the strongest of the S. cerevisiae 
promoters (Ohtake et al., 1988).  The YEp24-ScMET6 construct overexpressed 
methionine synthase activity approximately 10-fold when compared to the wild-
type methionine synthase activity in DAY4.1 cells.  The CaMET6 gene was 
expressed in the S. cerevisiae null mutant SDYα strain, a strain with no inherent 
methionine synthase.  The purification protocols for ScMet6p and CaMet6p were 
modified from the purification protocol reported in the literature (Burton and 
Sakami, 1969).  Table 3.1 shows the purification data obtained for CaMet6p and 
ScMet6p at each step of the purification procedure, and Figure 3.2 shows the 
Coomassie Brilliant Blue Stained SDS gels of CaMet6p and ScMet6p preparation 
at the different purification steps.  ScMet6p and CaMet6p were stable at high 
temperatures and at low pH, and in those purification steps both Met6 proteins 
remain stable in solution while other proteins were denatured and formed a pellet.  
The specific activity of CaMet6p and ScMet6p increased 6-10-fold during 
purification.  One liter of SDYα cells produced 5.5 mg of CaMet6p, which was 
purified to about 80% homogeneity (Figure 3.2A).  One liter of DAY4.1 cells 
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Figure 3.2:  A. Purification of CaMet6p.  Lanes: 1, Marker; 2, crude extract; 3, 
heat treatment; 4, acid treatment; 5, DEAE Sepharose column.  B. Purification of 
ScMet6p.  Lanes:  1, Marker; 2, crude extract; 3, heat treatment; 4, acid treatment; 






KINETIC ANALYSIS    
A non-radioactive enzyme assay was performed, using a modification of 
the procedure described by Drummond et al. (1995).  Kinetic experiments were 
performed to determine the substrate specificity of CaMet6p and ScMet6p.  
ScMet6p was believed to accept only polyglutamated substrates along with L-
homocysteine for catalysis (Burton et al., 1969).  The substrates (6R,S)5-
methyltetrahydropteroyl(mono-, di-. tri-, tetra-)glutamate and L-homocysteine, 
were each assayed with ScMet6p and CaMet6p.  The assays were performed in 
duplicate and fitted to the Michaelis Menten Equation.  The Km and kcat values 
calculated from the assays for CaMet6p and ScMet6p are listed in Table 3.2.  
Figure 3.3 shows the steady-state kinetic curves for CaMet6p, and Figure 3.4 



















Km (6R,S)-5-CH3–H4PteGlu1 (μM) 
kcat (1/min) 
Km (6R,S)-5-CH3–H4PteGlu2 (μM) 
kcat (1/min) 
Km (6R,S)-5-CH3–H4PteGlu3 (μM) 
kcat (1/min)  
Km (6R,S)-5-CH3–H4PteGlu4 (μM) 
kcat (1/min)  
Km L-homocysteine (μM)  
kcat (1/min)  
No activity 
 
113 ± 19 
  21 ± 1.1 
129 ± 25 
  24 ± 1.4 
120 ± 14 
  25 ± 0.9 
 No activity 
 
 109 ± 10 
  17 ± 0.4 
   84 ± 8 
  32 ± 0.8 
   94 ± 22 
  36 ± 2.4 
   14 ± 2.3   13 ± 2.6 






























Figure 3.3:  Steady State Kinetic Curves for CaMet6p.  Assays were performed 
in duplicate and averaged.  (6R,S)5-CH3–H4PteGlu1 ( ), (6R,S)5-CH3–H4Pte-
Glu2 ( ), (6R,S)5-CH3–H4PteGlu3 ( ), (6R,S)5-CH3–H4PteGlu4 ( ),L-




























Figure 3.4:  Steady State Kinetic Curves for ScMet6p.  Assays were performed in 
duplicate and averaged.  (6R,S)5-CH3–H4PteGlu1 ( ), (6R,S)5-CH3–H4Pte-Glu2 









Kinetic analyses using 5-CH3-H4PteGlun of different number of glutamates were 
performed over 6 different concentrations of (6R,S)-5-CH3-H4PteGlun and in the 
presence of saturating L-homocysteine, 2 mM.  It was proven that neither protein 
could accept a (6R,S)5-methyltetrahydropteroyl substrate containing only one 
glutamate.  Although the monoglutamated substrate did not bind, there was no 
significant difference among the Km or kcat values for the di-, tri-, or 
tetraglutamated substrates.  All the Km values were approximately 100 μM and all 
the kcat values were around 25/min.   
 The steady-state kinetic parameters for L-homocysteine were also 
measured.  These kinetic experiments were performed in the presence of 500 μM 
(6R,S)-5-CH3-H4PteGlu3, which was approaching saturation and sufficiently high 
to measure the effect of homocysteine independently.  Six increasing 
concentrations of L-homocysteine were assayed, giving apparent Km values for 








 The goal of this experiment was to explore the enzyme recognition site for 
homocysteine, using site-directed mutagenesis.  As described earlier, 
homocysteine is thought to be oriented in its binding pocket by ionic interaction 
between the substrate and amino acids Glu499 and Asp614.  To initiate 
mutagenesis studies, Asp614 was altered.  The mutations D614N and D614A 
were successfully created in the YEp24-CaMET6 plasmid.  The two plasmids, 
YEp24-CaMET6-D614N and YEp24-CaMET6-D614A, were transformed in the 
Scmet6 mutant cell strain, SDYα.  The only selection for this cell strain is the 
complementation of the Scmet6 mutation by the recombinant CaMet6p.  Neither 
plasmid with the mutation was able to compliment the Scmet6 mutant strain.   
To be able to express the mutated enzymes in the Scmet6 mutant strain, 
using a different selection marker, the HSYα strain was constructed.  This strain 
allowed for the use of the URA3 selection marker on the YEp24 plasmid, because 
the strain was rendered ura3-.  The mutated plasmids were then transformed into 
the HSYα strain, and plated on media supplemented with methionine.  A 0.5 liter 
liquid cell culture was grown, and samples were probed with CaMet6p polyclonal 
antibodies on a Western Blot (Figure 3.5).  The blot revealed that there was no 
mutant CaMet6p in the soluble fraction.   
 In order to bypass the apparent insolubility of the CaMet6 mutant protein, 
a vector expressing wild type CaMet6p as a GST fusion under the control of the 
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ScMET6 constitutive promoter was constructed in the pRS424 vector.  The GST 
fusion was successfully expressed (Figure 3.5) and complemented the SDYα 
Scmet6 mutant strain.  The fusion protein was successfully purified over 
glutathione agarose (Figure 3.6).  The fusion protein bound to the glutathione 
agarose column with a decreased binding capacity, and most of the fusion protein 
was in the flow-through (Figure 3.6).  The diminished binding capacity is due to 
the large size of the fusion protein, which is approximately 112 kDa.  The same 
site directed mutants, D614A and D614N, were created in the GST fusion 
construct, expressed in SDYα, and analyzed on an 8% SDS gel (Figure 3.7).  This 
gel revealed that GST fusions of the site directed mutants expressed, and this was 
confirmed with a Western Blot (Figure 3.7).  The GST fusions of D614A and 














Figure 3.5  8% SDS PAGE (A.) and Western Blot (B.) analysis of site-directed 
mutants, and wild-type GST-CaMet6p fusion probed with the polyclonal 
CaMet6p antibody.  Lanes: 1, protein ladder; 2, HSYα cell strain (negative 
control); 3, YEp24-CaMET6-D614N; 4, YEp24-CaMET6-D614A; 5, wild-type 



















Figure 3.6  8% SDS PAGE of the purification of the wild-type GST-CaMet6p 
fusion.  Lanes: 1, protein ladder; 2 + 3, crude extract; 4, pellet; 5 flow through; 6-

















Figure 3.7  A.  8% SDS PAGE GST-fusion site-directed mutants.  Lanes: 1, 
SDYα (negative control); 2, GST-D614N; 3, GST-D614A; 4, purified wild-type 
GST-CaMet6p fusion (positive control).  B.  Western blot analysis of the GST-
fusion mutants.  Lanes: 1, wild-type GST-CaMet6p fusion (positive control); 2, 
SDYα (negative control); 3, GST-D614N; 4, GST-D614A.  
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CAMET6 GENE DELETION 
Experiments in C. albicans were carried out to create CaMET6 deletion 
mutants, and to assess the viability of the resulting null mutant C. albicans strain.  
The parental C. albicans strain used was BWP17 (ura3/ura3 arg4/arg4 his1/his1), 
which is auxotrophic for uridine, arginine, and histidine (Wilson, 1999).  The first 
gene deletion experiments were performed using the URA3 cassette and the ARG4 
cassette separately.  Each cassette had 60 nucleotides at each end that 
complemented the sequences flanking the DNA coding for the CaMET6 ORF; 
through homologous recombination these cassettes should replace the CaMET6 
gene, as illustrated in Figures 3.8A and 3.9A.  The PCR amplified cassettes were 
transformed into the BWP17 strain, and the transformed cells were plated on 
media that either lacked uridine or lacked arginine.  Using this strategy, only the 
C. albicans cells that successfully integrated the URA3 or ARG4 cassettes should 
grow, but because C. albicans is diploid only one chromosomal allele is altered.  
After colonies appeared within 3-5 days, the genomic DNA purified from a 
number of colonies was tested for the deletion using PCR.  Figure 3.8B shows a 
0.8% agarose gel of the PCR of one transfomant performed using primers that 
flank the deleted region in the URA3 cassette transformants (The primer locations 
are indicated in Figure 3.8A).  The undeleted allele resulted in a 2800 bp PCR 
product, and the allele deleted with the URA3 cassette resulted in an 1800 bp PCR 
product.  The two bands proved that one copy of CaMET6 was effectively 
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removed from the genome, creating a heterozygous CaMET6/Camet6 mutant.  
Figure 3.9B shows a 0.8% agarose gel of the PCR tests performed using one 
ARG4 transformant.  The ARG4 cassette is the same size as the CaMET6 gene, 
and when using the primers that flank the deleted region, only one band appears.  
To test whether the ARG4 cassette had successfully replaced the CaMET6 gene, 
additional PCRs were performed using a 5’ primer that bound within the ARG4 
cassette and a 3’ primer that bound outside of the deleted region.  A 650 bp band 
corresponding to this amplification was obtained (Figure 3.9B), confirming that 
the ARG4 cassette replaced one copy of the CaMET6 gene, creating a 
heterozygous CaMET6/Camet6 mutant. 
 C. albicans is diploid, and a second experiment is needed in order to 
delete the second copy of CaMET6.  The URA3 heterozygous strain was therefore 
transformed with the ARG4 cassette, and the ARG4 heterozygous strain was 
transformed with the URA3 cassette.  All of the transformations were plated on 
agar plates that lacked uridine and arginine, and contained histidine and 
methionine.  No colonies resulted from the second round of deletion experiments, 
consistent with the notion that the transformations were successful, but the double 





Figure 3.8 A. 
 
 
















Figure 3.8 (continued) A.  A schematic of homologous recombination occurring 
after transformation with the URA3 cassette, and primer binding locations.  B.  
Analysis of URA3 transformant strains. Low range DNA marker, lane M.  PCR 
analysis of genomic DNA from the BWP17 strain amplified with FL-5DR and 
FL-3DR, lane 1.  PCR analysis genomic DNA from BWP17 URA3 transformant 
amplified with FL-5DR and FL-3DR, lane 2.  PCR amplification of the CaMET6 
gene with FL-5DR and FL-3DR results in a 2800 bp product, and amplification of 











Figure 3.9 A.  
 
 
Figure 3.9 B. 


















Figure 3.9 (continued) A.  A schematic of homologous recombination occurring 
after transformation with the ARG4 cassette.  The detection primers are listed in 
Table 2.1.  B.  Analysis of ARG4 transformants.  Low range DNA marker, lane 
M.  PCR analysis of genomic DNA from the BWP17 strain amplified with FL-
5DR and FL-3DR, lane 1; ARG4-1012-5DR and FL-3DR, lane2.  PCR analysis 
genomic DNA from BWP17 ARG4 transformants amplified with ARG4-1012-
5DR and FL-3DR, lane 3; FL-5DR and FL-3DR, lane 4.  PCR amplification of 
the CaMET6 gene with FL-5DR and FL-3DR results in a 2800 bp product, and 
amplification of the ARG4 cassette also results in a 2800 bp product.  PCR 
amplification of the ARG4 cassette with ARG4-1012-5DR and FL-3DR results in 
a 650 bp product, and amplification of CaMET6 gene with the same primers 








ANALYSIS OF A CONDITIONAL CaMET6 MUTANT 
 Since I was unable to obtain a double null mutant C. albicans cell strain, I 
attempted to construct a conditional CaMET6 mutant using the PGAL1 cassette 
(Gerami-Nejad, 2004).  This cassette contains a URA3 selection marker and a 
GAL1 promoter, which was amplified from the plasmid pURA3-PGAL1-GFP.  
The PGAL1 cassette was then transformed into the ARG4 heterozygous 
CaMET6/Camet6 mutant strain where, through homologous recombination, the 
GAL1 promoter was inserted in front of the remaining copy of CaMET6 (Figure 
3.10A).  The selection of transformants was on media containing raffinose, 
galactose, and histidine, where only those that integrated the PGAL1 cassette would 
grow.  Colonies appeared after 7 days.  The resulting transformants were tested 
using PCR to confirm that the cassette had integrated in front of the CaMET6 
ORF (Figure 3.10B).  When amplified with the FL-5DR and FL-3DR primers 
there should be two PCR products, one at 2800 bp, which represents the ARG4 
cassette, and one at ~6000 bp which represents the PGAL1 cassette plus the 
CaMET6 ORF.  Only the 2800 bp product was observed (Figure 3.10B, lane 9), 
because the ~6000 bp region was too large to amplify.  The presence of the ARG4 
cassette was tested the same way as in the heterozygous CaMET6/Camet6::ARG4 
mutant, with the same results.  However, amplification with FL-5DR and URA3-
517-5DR primers confirmed the presence of the PGAL1 cassette in front of the 
remaining CaMET6 ORF (Figure 3.10B, lane 11).  An attempt was made to 
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amplify the PGAL1 cassette, and the CaMET6 ORF, using primers GAL1-5DR and 
FL-3DR, but this product was also large and, again, did not amplify (Figure 
3.10B, lane 12). 
 The GAL1 promoter is induced by galactose and repressed by glucose 
(Berman, 2002; Srikantha, 1996).  Under inducing conditions, in the presence of 
galactose, the conditional CaMET6 mutant strain grows in a manner similar to 
that of the heterozygous C. albicans mutants.  Under repressive conditions, in 
media containing glucose and histidine, the conditional CaMET6 mutant strain 
did not grow (Figure 3.11A).  However, it did grow on media containing glucose, 
histidine, and methionine.  A Western Blot revealed that even under repressing 
conditions (glucose), CaMET6 was still expressed at low amounts (Figure 3.11B). 
 To estimate the effect of the conditional mutation on C. albicans 
metabolism, growth curves were measured for the wild type and the conditional 
mutant in the presence of three concentrations of methionine: the results are 
shown in Figure 3.12.  Growth rates for the wild type, which can synthesize the 
amino acid, is independent of exogenous methionine.  The culture reaches half its 
stationary concentration in 9 hours.  The conditional mutant grown under 
repressing conditions, in glucose, and does not grow in the absence of exogenous 
methionine.  However its time to half stationary levels are 56, 42, and 34 hours 
when supplemented with 10, 25, and 50 μM methionine respectively. 
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Figure 3.10 A. 
 
  

















Figure 3.10 (continued) A.  A schematic of homologous recombination 
occurring after transformation with the PGAL1 cassette into the heterozygous ARG4 
mutant, and primer binding.  B.  Analysis of ARG4 transformants.  PCR Analysis 
of PGAL1 transformants.  Genomic DNA from met6::ARG4 heterozygous mutant 
amplified with FL-5DR and FL-3DR, lane 1; ARG4-1012-5DR and FL-3DR, 
lane2; URA3-517-5DR and FL-5DR, lane 3; GAL1-5DR and FL-3DR, lane 4.  
PCR analysis of genomic DNA from the BWP17 strain amplified with FL-5DR 
and FL-3DR, lane 5; ARG4-1012-5DR and FL-3DR, lane 6; URA3-517-5DR and 
FL-5DR, lane 7; GAL1-5DR and FL-3DR, lane 8.  Genomic DNA from the 
conditional mutant amplified with FL-5DR and FL-3DR, lane 9; ARG4-1012-
5DR and FL-3DR, lane 10; URA3-517-5DR and FL-5DR, lane 11; GAL1-5DR 













          
Figure 3.11 A.  Serial 10-fold dilutions of a liquid culture containing the 
conditional mutant.  Media:  1, medium containing galactose and histidine; 2, 
medium containing glucose, histidine, and methionine; 3, medium containing 
glucose and histidine.  B.  Western Blot analysis of cellular extracts probed with 
the polyclonal CaMet6p antibody.  Conditional mutant induced with galactose, 
lane 1.  Conditional mutant repressed with glucose, and supplemented with 
methionine, lane 2. 
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Figure 3.12 A. 
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Figure 3.12 B. 
Conditional Mutant
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Figure 3.12 (continued).  Comparison of growth rates for wild type and 
conditional mutant.  Cultures were grown in triplicate and averaged.  A.  The 
growth rate for wild-type C. albicans in the presence of 10 (▲), 25 (●), and 50 
(▼) μM Methionine.  B. Growth curves for the conditional Camet6 mutant in the 












CHAPTER 4: DISCUSSION 
MEASURING KINETIC PARAMETERS 
Complementation of the Scmet6 mutant strain by both C. albicans and S. 
cerevisiae Met6 proteins, demonstrated that the two enzymes have similar 
activities, and function similarly under in vivo conditions.  The specific activity of 
CaMet6p and ScMet6p during purification increased only 6-10 fold due to the 
overexpression of the enzymes in the crude extract.  The purified enzymes were 
used for kinetic analysis.  The behavior of CaMet6p and ScMet6p are very 
similar, consistent with their high sequence homology.  Both enzymes require at 
least two glutamates for 5-CH3-H4PteGlun to be a substrate.  These results are 
consistent with a previous study that showed the ScMet6 enzyme requires at least 
a diglutamated substrate (Burton et al., 1969).  That same study reported a Km 
value for (6R,S)5-CH3-H4PteGlu2 of 430 μM and a Km value for (6R,S)5-CH3-
H4PteGlu3 of 380 μM, which are approximately four times higher than the values 
observed in the present experiments.  The use of recombinant protein, a different 
method of synthesizing substrate, and a modified assay can account for these 
differences.  Similar Km values for the (6R,S)5-CH3-H4PteGlu2 and the (6R,S)5-
CH3-H4PteGlu3 substrates were reported in another study by McClurg, 410 μM 
and 350 μM respectively (McClurg, 1996), but the kcat values for the di- and 
triglutamated substrates was reported to be about 25/min, identical to our values.  
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McClurg also assayed a heptaglutamated substrate, which resulted in a much 
lower Km value, 18 μM. 
 Previous studies, and my work, show that both CaMet6p and ScMet6p  
were not able to use the monoglutamated form of (6R,S)-5-CH3-H4PteGlun as a 
measurable substrate.  This observation might mean that the enzymes did not bind 
to the substrate, or that the substrate bound to the enzymes at a site or in an 
orientation not contributing to catalysis.  Experiments were therefore performed 
measuring the rate of activity for the (6R,S)-5-CH3-H4PteGlu3 substrate in the 
presence of increasing concentration of the (6R,S)-5-CH3-H4PteGlu1 as a potential 
inhibitor.  In these experiments, there was no evidence that the monoglutamated 
derivative was able to compete with polyglutamated substrate.  This observation 
is consistent with the concept that the monoglutamated derivative does not bind to 
the active site of the enzymes at any reasonable concentration. 
SITE-DIRECTED MUTAGENESIS 
 The D614N and D614A site-directed mutant forms of CaMet6p were 
constructed to implement a strategy for the study of important active site residues.  
These mutant forms of the CaMET6 gene were not detected in the soluble fraction 
of cell extracts.  This suggested that these mutants failed to fold properly.  To 
solve this problem, a GST fusion wild type CaMet6p was expressed.  The same 
site-directed mutants were created as GST fusions, and these constructs were 
successfully expressed.  GST is known to enhance protein solubility, and facilitate 
 100
protein purification (Busso et al., 2005).  This strategy will allow for the isolation 
of various site-directed mutant proteins, and the kinetic characterization of those 
mutants.             
CaMET6 GENE DELETION 
Initial attempts to create a viable CaMET6 double null mutant using the 
PCR-based gene disruption method were unsuccessful, most likely because the 
double disruption was lethal.  After the first round of transformations, one copy of 
CaMET6 was completely replaced by a selection cassette.  This was successful 
with both the URA3 and the ARG4 cassettes.  These heterozygous mutants grew 
normally.  However, subsequent attempts to delete the second copy of CaMET6 in 
the heterozygous mutants, using a different selection cassette, failed to produce 
viable homozygous Camet6 mutants.  Transformations from these experiments 
were plated, multiple times, on media supplemented with histidine and 
methionine, but no colonies appeared on the plates even when allowed to incubate 
for up to 10 days.  The results from these experiments indicate that CaMET6 is 
essential, and the double deletions are probably lethal since colonies did not grow 
even when supplemented with exogenous methionine.   
To further test this hypothesis, I created a conditional met6 mutant in C. 
albicans.  One copy of the CaMET6 gene was replaced with an ARG4 cassette, 
and a GAL1 promoter was inserted in front of the second copy.  Clearly, the 
conditional CaMET6 gene was being expressed and the protein was functional.  
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The GAL1 promoter was induced with galactose, and the conditional mutant grew 
well on media that contained galactose and histidine.  In contrast, when the GAL1 
promoter was repressed with glucose, the conditional mutant did not grow when 
supplemented only with histidine, but did grow when supplemented with both 
histidine and methionine.  These results suggested that C. albicans could import 
enough methionine to meet its metabolic needs.  However, this seems inconsistent 
with the observation that a double knockout cannot grow even when supplied with 
exogenous methionine.    It may be that the enzyme has an additional function that 
is essential to cell growth.   
To help elucidate the essential nature of the met6 gene, the conditional 
mutant was further analyzed using a Western Blot.  The CaMet6 protein levels 
were compared between the induced conditional mutant and the repressed 
conditional mutant, revealing that even though the GAL1 promoter was repressed, 
the CaMet6 protein was still expressed, although at much a lower level than 
occurred under inducing conditions.  This confirms previous reports that the 
GAL1 promoter is not completely repressed in glucose (Berman, 2002; Srikantha, 
1996).  These findings also indicate that whereas C. albicans is able to import 
sufficient methionine from the media to survive, the CaMET6 gene probably has 
some other important role or roles in addition to the synthesis of methionine.  For 
example, even when expressed at low levels, the CaMET6 protein may overcome 
homocysteine buildup, and thereby avoid the affects of homocysteine toxicity 
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(Pascon et al., 2004; Jakubowski et al., 1991).  An accumulation of intracellular 
homocysteine is observed in both S. cerevisiae and S. pombe (Fujita et al., 2006).  
Thus, the additional growth defects, not rescued by methionine, could be caused 
by toxicity of intracellular homocysteine.  Homocysteine has been reported to 
interfere with purine biosynthesis and sterol biosynthesis (Hatanaka et al., 1974; 
McCammon et al., 1981).   
Disruption mutants of methionine synthase in S. cerevisiae and 
Aspergillus nidulans can be fully rescued by methionine, which contrasts with my 
results (Kacprzak et al., 2003; Suliman et al., 2005).  Pascon et al. showed that a 
met6 mutant strain of Cryptococcus neoformans is not viable without methionine, 
but does grow at a slow rate when supplemented with methionine (Pascon, 2004).  
This is similar to the situation we have observed for C. albicans, where the 
repressed conditional mutant grows about six times more slowly than wild type 
under conditions that mimic intercellular fluids (10 μM methionine).   
 The C. neoformans met6 mutant was also avirulent in a mouse inhalation 
model, and is more susceptible to current anti-fungal drugs (Pascon et al., 2004).  
Seong et al. observed that a methionine synthase gene (msy1) deletion mutant of 
Fusarium graminearum is defective in aerial hyphal grown even in presence of 
methionine (Seong et al., 2005).  Likewise, Fujita et al. reported that disruption of 
the methionine synthase gene (met26) in Schizosaccharomyces pombe leads to a 
requirement for both methionine and adenine (Fujita et al., 2006).  It is reasonable 
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to assume that C. albicans conditional mutant would behave like these cases, and 
also that a drug repressed wild-type strain would be similarly avirulent. 
CONCLUSION 
The work presented here provides a strong foundation for further study of 
cobalamin-independent methionine synthase as anti-fungal drug target.  There is 
still a lot to learn about the mechanism of action of the cobalamin-independent 
enzymes.  For example, no known intermediate or catalytic residues have been 
specifically identified.  Understanding how these enzymes catalyze this important 
reaction may aid in the design of potent inhibitors.  The gene disruption 
experiments in C. albicans show the good possibility that cobalamin-independent 
methionine synthase can be an effective anti-fungal drug target.  The repressed 
conditional mutant does express a low amount of methionine synthase, and may 
be a good model for the activity of the enzyme in the presence of an inhibitory 
drug.  The phenotype of a methionine synthase mutant seems to be more 
complicated than just methionine auxotrophy.  The growth defects observed in C. 
albicans could be due to the toxic effect of homocysteine buildup or some other 





 Numerous attempts have been made to crystallize both ScMet6p and 
CaMet6p for the purpose of structure determination, but with no success.  Efforts 
are underway to use other Met6 proteins from different species of pathogenic 
fungi for this purpose.  Other pathogenic fungi of interest include Cryptococcus 
neoformans and Wangiella dermatitidis.  The C. neoformans genome has been 
sequenced, and cDNA is available through http://www.genome.ou.edu/cneo.html. 
Wangiella dermatitidis will be a challenge, because its genome is not sequenced, 
and its genome contains introns.  The MET6 gene will be identified through 
sequence homology with other MET6 genes, and cDNA will need to be obtained, 
or the gene altered to remove introns.  
Inhibitor Design 
 Anti-folates are a major class of known drugs with wide utility.  Since 
methionine synthase is a folate enzyme, it is reasonable to test some as inhibitors.  
Methotrexate, folinic acid, spermine, and sperimidine, were in fact tested against 
ScMet6p, but none inhibited enzyme activity.  My kinetic work has shown that 
Met6 proteins need at least a diglutamated substrate to bind in the active site, and 
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the same charge requirement may be true for inhibitors.  The potential inhibitors 
that were tested were all monoglutamated, and may not have bound to the 
enzymes.  In order to find an effective inhibitor, folate substrate analogues would 
need to be polyglutamated.  Then dose responses, and kinetic analyses can be 
performed to determine the effectiveness of the potential inhibitors. 
 Inhibitors can be designed by analyzing the structures of cobalamin-
independent methionine synthase from Arabidopsis thaliana, and Thermotoga 
maritima.  These structures have substrate bound, and give insight into how the 
two substrates bind in the active site.  From this, an inhibitor consisting of a 
homocysteine-5-CH3-H4-PteGlun fusion may be developed.  Further study may 
also suggest the chemistry and geometry for a transition state analog.  Similar to 
what was done with betaine homocysteine methyltransferase, this potential 
transition state analog can be used to further study binding contacts between the 
substrates and the enzyme (Evans et al., 2002; Castro et al., 2004).  
Site Directed Mutagenesis 
  Once purified mutant forms of CaMet6p are obtained, they can be 
kinetically characterized, and compared to the wild-type data.  Pursuing these 
experiments will give insight into the active site of the enzymes, and possibly 
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Glycerol 







Polyethyleneglycol (PEG) 3350 
Potassium chloride 
Serine 
Sodium dodecyl sulfate 
Taq DNA polymerase 
Trizma® (Tris base) 
Tryptone peptone 
Yeast Nitrogen Base 
EM Science, Cherry Hill, NJ 
Sigma, St. Louis, MO 
Sigma, St. Louis, MO 
Invitrogen,  
Sigma, St. Louis, MO 
Sigma, St. Louis, MO 
Sigma, St. Louis, MO 
New England Biolabs,  
Sigma, St. Louis, MO 
Sigma, St. Louis, MO 
Sigma, St. Louis, MO 
New England Biolabs, , MA   
Sigma, St. Louis, MO 
Sigma, St. Louis, MO 
Difco Laboratories, Detroit, MI 










YM (minimal media) 
7 g Yeast Nitrogen Base w/o amino acids 




100 ml of 20% glucose 
10 ml of 100X amino acids as needed up to 1 Liter total 
YPD (rich media) 
20 g tryptone 
10 g yeast extract 
900 ml ddH2O 
20 g agar (only when making plates) 
autoclave 
Then add: 




RbCl competent cells (e. coli) 
1) Streak desired E. coli strain on fresh LB plate. Grow overnight at 37°C.  
2) Inoculate a single colony into 10 ml LB. Grow overnight, shaking at 37° C.  
3) Inoculate about 1 ml into 200 ml LB in a 2 L flask. Shake at 37°C until OD600 
= 0.5.  
4) Chill flask in ice-water 5 minutes.  
5) Spin 5 minutes at 6,000 rpm in GS3 rotor.  
6) Resuspend pellet in 80 ml ice cold Buffer 1.  
7) Chill in ice-water 5 minutes.  
8) Spin 5 minutes at 6,000 rpm in GS3 rotor.  
9) Resuspend pellet in 8 ml ice cold Buffer 2.  
10) Chill in ice-water 15 minutes.  
11) Make 100 μl aliquots in 1.5 ml Eppendorf tubes, and store at –70oC. 
Buffer 1(500 ml) Buffer 2 (100 ml) 
30 mM KOAc (1.47 g)  10 mM MOPS (0.21 g) 
100 mM RbC12 (6.04 g)  75 mM CaCl2 (1.10 g) 
10 mM CaC12 (0.74 g)  10 mM RbCl2 (0.12g) 
50 mM MnC12-4H20 (4.94 g)  15% glycerol (15 ml) 
15% glycerol (75 ml) 
pH to 5.8 with dilute acetic acid pH to 6.5 with 1 M KOH 
sterile filter sterile filter 
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LURIA BERTANI (LB) MEDIA 
10 g peptone 
5 g yeast extract 
5 g NaCl 




E. coli transformation 
1) Thaw competent cells on ice. 
2) Add 1 μl of DNA to one tube of competent cells, and incubate on ice 40-60 
minutes. 
3) Heat shock at 42oC for 90 seconds. 
4) Add an equal volume of LB (no antibiotics) to the tube, and incubate on ice for 
2 minutes.  
5) Incubate the tube at 37oC for 30-60 minutes. 





YEAST TRANSFORMATION (“THE BEST METHOD”, GIETZ LAB) 
1) Start a 5 ml overnight culture of the yeast cells to be transformed, in YPD. 
2) Next morning, inoculate 25 ml of YPD with 1 ml of the overnight culture. 
Allow cells to grow to A600 = 1.0.  
3) Centrifuge at 5000 rpm for 5 minutes.  
4) Resuspend the cells in 3 ml of ddH2O, and centrifuge for 5 minutes.  
5) Resuspend the cell pellet in 1 ml of 100 mM LiAc and incubate for 10 min at 
30° C. (you can keep the cells overnight at 4oC if necessary) 
6) Place 100 μl of cells from the previous step into a 1.5 ml tube for each 
transformation reaction. 
7) Spin the suspension at top speed in a microcentrifuge for 5 sec.  Remove the 
supernatant with a micropipette. 
8) Add the following components into the tube on top of the cell pellet in this 
order: 
• 240 µL of PEG 3,350 (50% w/v)  
• 36 µL 1.0 M. LiAc  
• 15 µL SS-DNA (10.0 mg/ml)  
• 5.0 µL of plasmid or linear DNA  
• 64 µL of sterile ddH2O.  
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9) Vortex the cell pellet for at least 1 min to resuspend the cell pellet in the 
transformation mix. 
10) Incubate the cells for 30 minutes at 30°C.  
11) Incubate the cells for 20 minutes at 42°C.  
12) Pellet the cells at top speed in a microcentrifuge for 10 sec. Remove the 
supernatant using a micropipette. 
13) Add 200-400 µL of sterile ddH2O water and leave at room temperature for 5 
minutes, and resuspend by slowly pipetting up and down. 
14) Plate the cell suspension onto 1 or 2 plates of omission medium that selects 
for the presence of the plasmid. If necessary, let the plates sit a little to absorb 
the mixture.  Colonies should be visible in 2 -4 days at 30° C. 
SYNTHESIS OF (6R,S)-5-CH3-H4-PTEGLUN FROM H4PTEGLUN 
 (6R,S)-5-CH3-H4PteGlun was synthesized from H4PteGlun (Schirck’s 
Laboratories Jona, Switzerland) by a modification of the procedure of Yeo and 
Wagner (1992).  40 μmol of PteGlun, 20-40 mg depending on the number of 
glutamates, is weighed in a 2 ml free-standing screwcap tube with a round 
bottom.  Make a 265 μM Pb(NO3)2 solution by first making 26.5 mM Pb(NO3)2 
solution in ddH2O, then diluting 100 times with 10 mM Tris-Cl, pH 7.5.  Add 200 
μl of the 265 μM Pb(NO3)2 to the weighed PteGlun.  To dissolve the PteGlun, 
adjust the pH of the solution to 7.5 using a 5 M NaOH solution, then vortex.  Spot 
small amounts on pH paper to check the pH.  Add 5 M NaOH as needed, and 
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continue until all the PteGlun is dissolved resulting in a clear, dark yellow 
solution.  PteGlun with higher numbers of glutamates will require considerable 
vortexing and more NaOH to dissolve completely.  Check the spectrum of a 10-4 
dilution in 10 mM Tris-Cl, pH 7.5; it should show peaks at 282nm and at 350nm. 
 PteGlun is then reduced to H4PteGlun using NaBH4.  In this reaction, 
Pb(NO3)2 is used as a catalyst to reduce the amount of NaBH4 used.  It is 
important to use fresh active NaBH4, especially since it is hygroscopic.  Add a 
stir bar to the tube containing the PteGlun and move it to the cold room.  Use an 
eppendorf tube rack to hold the tube, while stirring at top speed.  Add 5 mg 
NaBH4 (132 μmol) to 25 μl ddH2O, and then add 5 μl of this solution to the 
PteGlun 5 times over 20 minutes.  The pH of this solution is maintained by adding 
2-5 μl of 20%(w/v) citric acid per addition of NaBH4.  Once all of the NaBH4 is 
added, move to room temperature, and flush the tube with argon or N2, and stir at 
maximum speed, in the dark, for 2 hours. 
 Next, cool the tube to 4oC, and lower the pH to 5.0 by adding 5 M Acetic 
Acid, some bubbling will occur, to destroy the excess NaBH4.  Then bring the pH 
back to 7.8 using 5 M NaOH.  The product should be H4PteGlun.  Check the 
spectrum of a 10-4 dilution in 10mM Tris-Cl, pH 7.5.  There should be a peak at 
298nm and a trough at 244nm. 
 The H4PteGlun is then condensed with formaldehyde to produce CH2-
H4PteGlun.  6.4 μl (80 μmol) of 37% formaldehyde is added, and the tube is 
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flushed with argon (N2).  The tube is incubated at 45oC for 15 minutes, in the dark 
to convert H4PteGlun to CH2-H4PteGlun.   
 CH2-H4PteGlun is then reduced to 5-CH3-H4PteGlun using NaBH4.  Add 
10 mg of NaBH4 (264 μmol) to 50 μl of ddH2O.  Add 10 μl of this solution to the 
tube 5 times over 20 minutes.  Maintain the pH by adding 2-5 μl of 20%(w/v) 
citric acid per addition of NaBH4.  Once all of the NaBH4 is added, flush the tube 
with argon (N2) and incubate at 45οC for 60 minutes in the dark.   
 Remove the stir bar from the tube, and cool to 4oC.  Add 2-
mercaptoethanol to 50 mM, and adjust the pH to 5.0 with 5 M Acetic Acid to 
destroy any excess NaBH4.  Vortex the tube until there is no more bubbling.  
Bring the pH back to 7.5 using 5 M NaOH.  The product should be 5-CH3-
H4PteGlun.  Check the spectrum of a 10-4 dilution.  There should be a peak at 290-
292 nm, and a trough at 248 nm.   
To test the yield, dilute 2 μl of the product into 200 μl 10 mM Tris-Cl pH 
7.5.  Then add 10 μl of this dilution into 400 μl of 10 mM Tris-Cl pH 7.5.  Add 
100 μl 5 M HCl/60% formate, and heat the solution at 80oC for 10 minutes.  Cool 
the solution to room temperature and read the spectrum.  A peak at 350 nm is 
diagnostic of H4-PteGlun, and the lack of a peak indicates CH3-H4-PteGlun.  The 
(6R,S)5-CH3-H4-PteGlun should be stored under argon(N2) in dark at –20oC. This 
procedure gives ~93% yield, and the final product has less than 3% H4PteGlun 
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based on its reaction with 5 M HCl/60% formate.  For long term storage, can be 
stored at –80oC for at least a year (Drummond et al., 1995). 
SYNTHESIS OF L-HOMOCYSTEINE FROM L-HOMOCYSTEINE THIOLACTONE   
L-homocysteine was prepared from L-homocysteine thiolactone by 
alkaline hydrolysis (Drummond et al., 1995).  Fifty mg of L-homocysteine 
thiolactone (Sigma) is weighed and dissolved in 1.7 ml ddH2O.  Bubble an 800 
mM NaOH solution with argon (N2) for 5 minutes, then 830 ml of the NaOH 
solution is added to the L-homocysteine thiolactone solution.  Incubate this 
solution at 45oC for 6 minutes.  Adjust the pH to 5.0 using 5.0 M acetic acid, 
checking the pH with pH paper.  Dilute the solution to 3.3 ml using argon (N2) 
bubbled ddH2O, resulting in a ~100 mM solution.  Store L-homocysteine in 1 ml 
aliquots at –80oC. 
 Titrate the L-homocysteine solution with 5,5’-dithiobis-2-nitrobenzoic 
acid (DTNB) to check the actual concentration.  Make a 10 mM DTNB stock 
solution in 50 mM potassium phosphate buffer pH 7.0.  Dilute the L-
homocysteine solution 100 fold, and add 50 μl to 900 μl of 100 mM sodium 
phosphate buffer pH 8.0.  To this solution add 50 ml of the DTNB stock, and let it 
stand for 2-3 minutes.  Then read the spectrum of the solution at 412 nm.  
Subtract the buffer blank, and divide the corrected absorbance at 412 nm by the 
extinction coefficient for the liberated thionitrobenzoate anion (13.6 mM-1) to 
calculate the actual L-homocysteine concentration. 
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5X LOADING BUFFER FOR DNA SAMPLES 
3.0 ml Glycerol 
0.025 g Bromophenol Blue 
0.025 g Xylene Cyanol FF  
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